Ada standards of medical care 2013 final 21 dec 2012 (2)
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Ada standards of medical care 2013 final 21 dec 2012 (2)

on

  • 698 views

Recomendaciones de la Asociacion americana de diabetes

Recomendaciones de la Asociacion americana de diabetes

Statistics

Views

Total Views
698
Views on SlideShare
698
Embed Views
0

Actions

Likes
0
Downloads
26
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • “Standards of Medical Care in Diabetes—2013” comprises all of the current and key clinical recommendations of the American Diabetes Association (ADA) <br /> These standards of care are intended to provide clinicians, patients, researchers, payers, and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care <br /> While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided; specifically titled sections of the standards address children with diabetes, pregnant women, and people with prediabetes <br /> These standards are not intended to preclude clinical judgment or more extensive evaluation and management of the patient by other specialists as needed; for more detailed information about management of diabetes, refer to references <br /> The recommendations included are screening, diagnostic, and therapeutic actions that are known or believed to affect health outcomes of patients with diabetes favorably; a large number of these interventions have been shown to be cost-effective <br /> The slides are organized to correspond with sections within the “Standards of Medical Care in Diabetes—2013” <br /> While not every section in the document is represented, these slides do incorporate the most salient points from the Position Statement <br /> These standards of care are revised annually by the ADA’s multidisciplinary Professional Practice Committee, incorporating new evidence; subsequently, they are reviewed and approved by the Executive Committee of ADA’s Board of Directors <br />
  • The slide deck, mirroring “Standards of Medical Care in Diabetes—2013,” is divided into ten separate sections, I.–X. <br /> Each of the ten sections includes text and tables from “Standards of Medical Care in Diabetes—2013” <br /> The title slide at the beginning of each of the ten sections includes the number of slides in that section and a list of the slide titles <br />
  • The American Diabetes Association has developed a grading system for clinical recommendations (Table 1) <br /> This grading system was used to clarify and codify evidence that forms the basis for each of the recommendations in the “Standards of Medical Care in Diabetes—2013” <br /> The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E <br /> This slide summarizes the description for each of these levels of evidence <br />
  • “Standards of Medical Care in Diabetes—2013” comprises ten sections <br /> Section I. Classification and Diagnosis includes seven slides: <br /> Classification of Diabetes <br /> Criteria for the Diagnosis of Diabetes (5 slides) <br /> Prediabetes: IFG, IGT, Increased A1C <br />
  • The classification of diabetes includes four clinical classes <br /> Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency) <br /> Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance) <br /> Other specific types of diabetes due to other causes; e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemical-induced diabetes (such as in the treatment of HIV/AIDS or after organ transplantation) <br /> Gestational diabetes mellitus (GDM; diabetes diagnosed during pregnancy that is not clearly overt diabetes) <br /> Some patients cannot be clearly classified as having type 1 or type 2 diabetes <br /> Clinical presentation and disease progression vary considerably in both types of diabetes <br /> Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis <br /> Similarly, patients with type 1 diabetes may have a late onset and slow (but relentless) progression despite having features of autoimmune disease <br /> Such difficulties in diagnosis may occur in children, adolescents, and adults <br /> The true diagnosis may become more obvious over time <br />
  • Table 2, current diagnostic criteria for the diagnosis of diabetes, is divided into five slides <br /> On this slide, all four criteria are included: <br /> A1C ≥6.5% <br /> OR <br /> Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) <br /> OR <br /> 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during an OGTT <br /> OR <br /> A random plasma glucose ≥200 mg/dL (11.1 mmol/L), in patients with classic symptoms of hyperglycemia or hyperglycemic crisis <br /> The subsequent four slides examine each of the four criteria in greater detail <br />
  • A1C <br /> In 2009, an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended the use of the A1C test to diagnose diabetes, with a threshold of ≥6.5%1, and ADA adopted this criterion in 20102 <br /> The diagnostic test should be performed using a method certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay3 <br /> Although point-of-care A1C assays may be NGSP certified, proficiency testing is not mandated for performing the test, so use of these assays for diagnostic purposes could be problematic3 <br /> The A1C has several advantages to the FPG and OGTT, including greater convenience (since fasting is not required), evidence to suggest greater preanalytical stability, and less day-to-day perturbations during periods of stress and illness3 <br /> These advantages must be balanced by greater cost, the limited availability of A1C testing in certain regions of the developing world, and the incomplete correlation between A1C and average glucose in certain individuals3 <br /> In addition, HbA1C levels may vary with patients’ race/ethnicity4,5 <br />
  • Fasting Plasma Glucose (FGP) <br /> The established glucose criteria for the diagnosis of diabetes (FPG and 2-hour plasma glucose [next slide]) remain valid as well1 <br /> Just as there is less than 100% concordance between the FPG and 2-h PG tests, there is no perfect concordance between A1C and either glucose-based test1 <br /> Analyses of National Health and Nutrition Examination Survey (NHANES) data indicatethat, assuming universal screening of the undiagnosed, the A1C cut point of ≥6.5% identifies one-third fewer cases of undiagnosed diabetes than a fasting glucose cut point of ≥126 mg/dL (7.0 mmol/L)2 <br /> However, in practice, a large portion of the diabetic population remains unaware of their condition1 <br /> Thus, the lower sensitivity of A1C at the designated cut point may well be offset by the test’s greater practicality, and wider application of a more convenient test (A1C) may actually increase the number of diagnoses made1 <br />
  • 2-hour plasma glucose (2-h PG) <br /> The 2-hour plasma glucose test should be performed as described by the World Health Organization (WHO), using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water <br /> The established glucose criteria for the diagnosis of diabetes (FPG, previous slide, and 2-h PG) remain valid <br />
  • Random Plasma Glucose <br /> As with most diagnostic tests, a test result diagnostic of diabetes should be repeated to rule out laboratory error, unless the diagnosis is clear on clinical grounds, such as a patient with a hyperglycemic crisis or classic symptoms of hyperglycemia and a random plasma glucose ≥200 mg/dL <br /> It is preferable that the same test be repeated for confirmation, since there will be a greater likelihood of concurrence in this case <br /> For example, if the A1C is 7.0% and a repeat result is 6.8%, the diagnosis of diabetes is confirmed; however, if two different tests (such as A1C and FPG) are both above the diagnostic thresholds, the diagnosis of diabetes is also confirmed <br /> On the other hand, if two different tests are available in an individual and the results are discordant, the test whose result is above the diagnostic cut point should be repeated, and the diagnosis is made based on the confirmed test <br /> That is, if a patient meets the diabetes criterion of the A1C (two results ≥6.5%) but not the FPG (&lt;126 mg/dL or 7.0 mmol/L), or vice versa, that person should be considered to have diabetes <br />
  • In 1997 and 2003, the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus1,2 recognized an intermediate group of individuals whose glucose levels, although not meeting criteria for diabetes, are nevertheless too high to be considered normal <br /> This group was defined as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) <br /> IFG: fasting plasma glucose (FPG) of 100–125 mg/dL (5.6–6.9 mmol/L)* <br /> IGT: 2-hour plasma glucose (2-h PG) in the 75-g oral glucose tolerance test (OGTT) of 140–199 mg/dL (7.8–11.0 mmol/L) <br /> Individuals with IFG and/or IGT have been referred to as having prediabetes, indicating a relatively high risk for future development of diabetes <br /> IFG and IGT should not be viewed as clinical entities in their own right but rather risk factors for diabetes as well as cardiovascular disease (CVD) <br /> IFG and IGT are associated with obesity (especially abdominal or visceral obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension <br /> Individuals with an A1C of 5.7–6.4% should be informed of their increased risk for diabetes as well as CVD and counseled about effective strategies to lower their risks (see Section IV. Prevention/Delay of Type 2 Diabetes) <br /> *The World Health Organization (WHO) and a number of other diabetes organizations define the cutoff for IFG at 110 mg/dL (6.1 mmol/L) <br />
  • Section II. Testing for Diabetes in Asymptomatic Patients includes three slides: <br /> Recommendations: Testing for Diabetes in Asymptomatic Patients <br /> Criteria for Testing for Diabetes in Asymptomatic Adult Individuals (2 slides) <br />
  • Recommendations for testing for diabetes in asymptomatic patients are summarized on this slide; testing should be considered in adults of any age with BMI ≥25 kg/m2 and one or more of the known risk factors for diabetes <br /> For many illnesses, there is major distinction between screening and diagnostic testing; however, for diabetes, the same tests would be used for “screening” as for diagnosis <br /> A1C, fasting plasma glucose (FPG), or 2-hour oral glucose tolerance test (2-h OGTT) are appropriate to test for diabetes <br /> The same assays used for testing for diabetes will also detect individuals with prediabetes <br /> In adults, prediabetes and diabetes meet established criteria for conditions in which early detection is appropriate; both conditions are common, increasing in prevalence, and impose significant health burdens <br /> There is a long presymptomatic phase before the diagnosis of type 2 diabetes is usually made; relatively simple tests are available to detect preclinical disease <br /> Additionally, the duration of glycemic burden is a strong predictor of adverse outcomes, and effective interventions exist to prevent progression of prediabetes to diabetes (see Section IV. Prevention/Delay of Type 2 Diabetes) and to reduce risk of complications of diabetes (see Section VI. Prevention and Management of Diabetes Complications) <br />
  • The three primary criteria for testing for diabetes in asymptomatic adult individuals(Table 4) are summarized on two slides; this slide (Slide 1 of 2) includes: <br /> Testing should be considered in all adults who are overweight (BMI ≥25 kg/m2) and have additional risk factors1 <br /> Testing should be considered in adults of any age with BMI ≥25 kg/m2 and one or more of the known risk factors for diabetes listed on this slide1 <br /> There is compelling evidence that lower BMI cut-points suggest diabetes risk in some racial and ethnic groups1 <br /> In a large multiethnic cohort study, for an equivalent incidence rate of diabetes conferred by a BMI of 30 kg/m2 in whites, the BMI cutoff value was 24 kg/m2 in South Asians,25 mg/m2 in Chinese persons, and 26 kg/m2 in African Americans2 <br />
  • The three primary criteria for testing for diabetes in asymptomatic adult individuals(Table 4) are summarized on two slides; this slide (Slide 2 of 2) includes: <br /> In the absence of criteria (risk factors on previous slide), testing diabetes should begin at age 45 years <br /> If results are normal, testing should be repeated at least at 3-year intervals, with consideration of more frequent testing depending on initial results and risk status <br /> Age is a major risk factor for diabetes; therefore, testing of individuals (using A1C, FPG, or 2-hour OGTT) without other risk factors should begin no later than at age 45 years <br /> The rationale for the 3-year interval is that false negatives will be repeated before substantial time elapses, and there is little likelihood that an individual will develop significant complications of diabetes within 3 years of a negative test result <br /> Given the need for follow-up and discussion of abnormal results, testing should be conducted within the health care setting <br /> Community screening outside a health care setting is not recommended because people with positive tests may not seek, or have access to, appropriate follow-up testing and care <br /> Conversely, there may be failure to ensure appropriate repeat testing for individuals who test negative <br /> Community screening may also be poorly targeted; i.e., it may fail to reach the groups most at risk and inappropriately test those at low risk (the worried well) or even those already diagnosed <br />
  • Section III. Detection and Diagnosis of Gestational Diabetes Mellitus includes three slides: <br /> Recommendations: Detection and Diagnosis of GDM (2 slides) <br /> Screening for and Diagnosis of GDM (1 slide) <br />
  • Recommendations for the detection and diagnosis of gestational diabetes mellitus (GDM) are summarized on two slides; this slide (Slide 1 of 2) includes: <br /> Screen for undiagnosed type 2 diabetes at the first prenatal visit in those with risk factors, using standard diagnostic criteria (B) <br /> In pregnant women not previously known to have diabetes, screen for GDM at 24–28 weeks’ gestation, using a 75-g OGTT and the diagnostic cut points in Table 6 (see Slide 19) (B) <br /> As the ongoing epidemic of obesity and diabetes has led to more type 2 diabetes in women of childbearing age, the number of pregnant women with undiagnosed type 2 diabetes has increased1 <br /> Because of this, it is reasonable to screen women with risk factors for type 2 diabetes (see Table 4 , Slides 14 and 15,) for diabetes at their initial prenatal visit, using standard diagnostic criteria (see Table 2, Slides 6-10); women with diabetes found at this visit should receive a diagnosis of overt, not gestational, diabetes2 <br />
  • Recommendations for the detection and diagnosis of gestational diabetes mellitus (GDM)1 are summarized on two slides; this slide (Slide 2 of 2) includes: <br /> Screen women with GDM for persistent diabetes at 6–12 weeks’ postpartum, using the OGTT and nonpregnancy diagnostic criteria (E) <br /> Women with a history of GDM should have lifelong screening for the development of diabetes or prediabetes at least every 3 years (B) <br /> Women with a history of GDM found to have prediabetes should receive lifestyle interventions or metformin to prevent diabetes (A) <br /> Women with a history of GDM have a greatly increased subsequent risk for diabetes2; therefore, they should be screened for diabetes 6–12 weeks postpartum, using nonpregnant OGTT criteria, and followed for the development of diabetes or prediabetes (see Section II. Testing for Diabetes in Asymptomatic Patients) <br /> Because of their prepartum treatment for hyperglycemia, use of the A1C for diagnosis of persistent diabetes at the postpartum visit is not recommended3 <br /> Lifestyle interventions or metformin should be offered to women with a history GDM who develop prediabetes (see Section IV. Prevention/Delay of Type 2 Diabetes) <br /> For information on the National Diabetes Education Program campaign to prevent type 2 diabetes in women with GDM, see http://ndep.nih.gov/media/NeverTooEarly_Tipsheet.pdf <br />
  • GDM carries risks for the mother and neonate1 <br /> The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study,2 a large-scale (approximately 25,000 pregnant women) multinational epidemiologic study, demonstrated that risk of adverse maternal, fetal, and neonatal outcomes continuously increased as a function of maternal glycemia at 24–28 weeks, even within ranges previously considered normal for pregnancy. For most complications, there was no threshold for risk. These results have led to careful reconsideration of the diagnostic criteria for GDM <br /> After deliberations in 2008–2009, the International Association of Diabetes and Pregnancy Study Groups (IADPSG), an international consensus group with representatives from multiple obstetrical and diabetes organizations, including ADA, developed revised recommendations for diagnosing GDM. The group recommended that all women not known to have diabetes undergo a 75-g OGTT at 24–28 weeks of gestation <br /> Additionally, the group developed diagnostic cut points for the fasting, 1-h, and 2-h plasma glucose measurements that conveyed an odds ratio for adverse outcomes of at least 1.75 compared with the mean glucose levels in the HAPO study <br /> Current screening and diagnostic strategies, based on the IADPSG statement,3 are outlined in Table 6, which is summarized on this slide <br /> The National Institutes of Health is planning to hold a Consensus Development Conference on diagnostic criteria for GDM in 2013 <br />
  • Section IV. Prevention/Delay of Type 2 Diabetes includes two slides: <br /> Recommendations: Prevention/Delay of Type 2 Diabetes <br />
  • Recommendations for the prevention/delay of type 2 diabetes1 are summarized on two slides <br /> Slide 1 of 2 <br /> Individuals at high risk for developing type 2 diabetes (i.e., those with impaired fasting glucose [IFG], impaired glucose tolerance [IGT] or both) can be given interventions that significantly decrease rate of onset of diabetes <br /> Based on results of clinical trials and known risks of progression of prediabetes to diabetes, person with an A1C of 5.7%–6.4%, IGT or IFG should be counseled on lifestyle changes: 7% weight loss and moderate physical activity of at least 150 minutes/week <br />
  • Recommendations for the prevention/delay of type 2 diabetes1 are summarized on two slides <br /> Slide 2 of 2 <br /> Metformin has a strong evidence base and demonstrated long-term safety2 <br /> Metformin may be recommended for very high-risk individuals (those with a history of GDM, the very obese, and/or those with more severe or progressive hyperglycemia) <br /> Of note, in the Diabetes Prevention Program (DPP), metformin was not significantly better than placebo in those over age 60 years3 <br /> For other drugs, issues of cost, side effects, and lack of persistence of effect in some studies4 require consideration <br /> People with prediabetes often have other CVD risk factors, such as obesity, hypertension, and dyslipidemia; in the DPP and DPPOS, cardiovascular event rates have been very low, perhaps due to appropriate management of cardiovascular risk factors in all study arms5 <br />
  • Section V. Diabetes Care includes 41 slides (1 slide unless otherwise noted): <br /> Diabetes Care: Initial Evaluation <br /> Components of the Comprehensive Diabetes Evaluation (7 slides) <br /> Diabetes Care: Management <br /> Diabetes Care: Glycemic Control <br /> Recommendations: Glucose Monitoring (3 slides) <br /> Recommendations: A1C <br /> Correlation of A1C with Average Glucose (AG) <br /> Recommendations: Glycemic Goals in Adults (3 slides) <br /> Intensive Glycemic Control and Cardiovascular Outcomes: ACCORD <br /> Intensive Glycemic Control and Cardiovascular Outcomes : ADVANCE <br /> Intensive Glycemic Control and Cardiovascular Outcomes : VADT <br /> Glycemic Recommendations for Nonpregnant Adults with Diabetes (3 slides) <br /> Recommendations: Insulin Therapy for Type 1 Diabetes (2 slides) <br /> Recommendations: Therapy for Type 2 Diabetes (3 slides) <br /> Recommendations: Medical Nutrition Therapy <br /> Look AHEAD (Action for Health in Diabetes): Trial Halted Early <br /> Recommendations: Diabetes Self-Management Education and Support (2 slides) <br /> Recommendations: Physical Activity <br /> Recommendations: Psychosocial Assessment and Care <br /> Recommendations: Hypoglycemia (3 slides) <br /> Recommendations: Bariatric Surgery <br /> Recommendations: Immunization (2 slides) <br />
  • Initial evaluation of the patient with diabetes consists of a complete medical evaluation, which is performed to classify the diabetes, detect the presence of diabetes complications, review previous treatment and glycemic control in patients with established diabetes, assist in formulating a management plan, and provide a basis for continuing care <br /> Laboratory tests appropriate to the evaluation of each patient’s medical condition should be performed <br /> A focus on the components of comprehensive care (Table 7, see Slides 24-30), will assist the health care team to ensure optimal management of the patient with diabetes <br />
  • A focus on the components of comprehensive care (as outlined on this and the next 6 slides) will help ensure optimal management of the patient with diabetes <br /> Slide 1 of 7 (Part 1 of 3) <br /> The first component of the comprehensive diabetes evaluation is medical history <br /> Age, characteristics of diabetes onset, such as diabetic ketoacidosis (DKA) or an asymptomatic laboratory finding <br /> Eating patterns, physical activity habits, nutritional status, and weight history as well as growth and development in children and adolescents <br /> History of diabetes education <br /> Review of previous treatment regimens and response to therapy (i.e., A1C records) <br />
  • Slide 2 of 7 (Part 2 of 3) <br /> During a patient’s comprehensive diabetes evaluation, his or her current treatment of diabetes should be established, including medications, medication adherence and barriers thereto, meal plan, patterns of physical activity, and readiness for behavior change <br /> Results of glucose monitoring and patient’s use of data should also be determined <br /> This should include frequency, severity, and cause of diabetic ketoacidosis; hypoglycemic episodes and awareness of hypoglycemia; and frequency and cause of any severe hypoglycemia <br />
  • Slide 3 of 7 (Part 3 of 3) <br /> A history of diabetes-related complications is an important component of the comprehensive diabetes evaluation, as noted on this slide <br /> Microvascular disease may be signaled by retinopathy, nephropathy, or neuropathy <br /> Sensory neuropathy can include a history of lesions on the feet <br /> Sexual dysfunction and gastroparesis may be symptomatic of autonomic neuropathy <br /> Macrovascular-related complications include coronary heart disease (CHD), cerebrovascular disease, or peripheral artery disease (PAD) <br /> Other complications can include psychosocial problems or dental disease; patients should be appropriately referred when necessary <br />
  • Slide 4 of 7 (Part 1 of 2) <br /> A physical examination of the patient with diabetes includes <br /> Height, weight, and body mass index (BMI) <br /> Determination of blood pressure that includes orthostatic measurements when indicated <br /> A fundoscopic examination (patients should be appropriately referred when necessary) <br /> Palpation of the thyroid <br /> An examination of the skin for acanthosis nigricans and sites of insulin injection <br />
  • Slide 5 of 7 (Part 2 of 2) <br /> The physical examination includes a comprehensive examination of both feet <br /> During the inspection, palpation of the dorsalis pedis and posterior tibial pulses is conducted <br /> The presence or absence of patellar and Achilles reflexes should also be noted <br /> Proprioception, vibration, and monofilament sensation is also determined <br /> (See also Section VI. Prevention and Management of Diabetes Complications. Recommendations: Neuropathy Foot Care, Slides 105-108) <br />
  • Slide 6 of 7 <br /> This slide details the components of a laboratory evaluation <br /> If not available within the past 2-3 months, an A1C test is required <br /> If the following test results are not available or these tests were not performed during the previous year, the clinician should perform <br /> A fasting lipid profile, including total cholesterol, LDL cholesterol, and HDL-cholesterol levels as well as triglyceride level <br /> Liver function tests <br /> Urine albumin excretion test that includes a spot urine albumin/creatinine ratio <br /> A serum creatinine test that includes a calculated glomerular filtration rate (GFR) <br /> A thyroid-stimulating hormone (TSH) test in patients with type 1 diabetes, dyslipidemia, or in women older than 50 years of age <br />
  • Slide 7 of 7 <br /> Appropriate referrals for patients with diabetes include those outlined on this slide <br /> An eye care professional should be consulted for an annual dilated eye examination <br /> For women of reproductive age, family planning counseling is appropriate <br /> For those needing medical nutrition therapy (MNT), a referral to a registered dietitian is warranted <br /> Tools for diabetes self-management education (DSME) should be provided <br /> A dentist can provide a comprehensive periodontal examination <br /> Referral to a mental health professional may be needed <br />
  • People with diabetes should receive medical care from a team that may include physicians, nurse practitioners, physician’s assistants, nurses, dietitians, pharmacists, mental health professionals with expertise and a special interest in diabetes <br /> In this collaborative and integrated team approach, it is essential that individuals with diabetes assume an active role in their care <br /> The management plan should be formulated as a collaborative therapeutic alliance among the patient and family, the physician, and other members of the health care team <br /> A variety of strategies and techniques should be used to provide adequate education and development of problem-solving skills in the various aspects of diabetes management <br /> Implementation of the management plan requires that each aspect is understood and agreed to by the patient and the care providers and that the goals and treatment plan are reasonable <br /> Any plan should recognize diabetes self-management education (DSME) and on-going diabetes support as an integral component of care <br /> In developing the plan, consideration should be given to the patient’s age, school or work schedule and conditions, physical activity, eating patterns, social situation and cultural factors, and presence of complications of diabetes or other medical conditions <br />
  • In addition to an initial evaluation and management, diabetes care requires an assessment of glycemic control <br /> Two primary techniques available for health providers and patients to assess the effectiveness of the management plan on glycemic control are summarized on this slide <br /> Patient self-monitoring of blood glucose (SMBG) or interstitial glucose <br /> A1C <br /> A1C testing should be performed routinely in all patients with diabetes, at initial assessment and then as part of continuing care <br /> For any individual patient, the frequency of A1C testing depends on the clinical situation, treatment regimen used, and clinician judgment <br /> Recommendations for glucose monitoring, A1C testing, correlation of A1C with average glucose, glycemic goals in adults, intensive glycemic control and cardiovascular outcomes, and glycemic recommendations for many nonpregnant adults with diabetes are summarized in the following 14 slides <br />
  • Recommendations for glucose monitoring are summarized on three slides <br /> Slide 1 of 3 <br /> Patients on multiple-dose insulin (MDI) or insulin pump therapy should do SMBG at least prior to meals and snacks, occasionally postprandially, at bedtime, prior to exercise, when they suspect low blood glucose, after treating low blood glucose until they are normoglycemic, and prior to critical tasks such as driving (B) <br /> The frequency and timing of SMBG should be dictated by the particular needs and goals of the patient <br /> SMBG is especially important for patients treated with insulin to monitor for and prevent asymptomatic hypoglycemia and hyperglycemia <br /> The optimal frequency of SMBG for patients on nonintensive regimens, such as those with type 2 diabetes on basal insulin, is not known, although a number of studies have used fasting SMBG for patient or provider titration of the basal insulin dose <br />
  • Recommendations for glucose monitoring are summarized on three slides <br /> Slide 2 of 3 <br /> When prescribed as part of a broader educational context, SMBG results may be helpful to guide treatment decisions and/or patient self-management for patients using less frequent insulin injections or noninsulin therapies (E) <br /> When prescribing SMBG, ensure that patients receive ongoing instruction and regular evaluation of SMBG technique and SMBG results, as well as their ability to use SMBG data to adjust therapy (E) <br />
  • Recommendations for glucose monitoring1 are summarized on three slides <br /> Slide 3 of 3 <br /> Continuous glucose monitoring (CGM) with intensive insulin regimens can be a useful tool to lower A1C in selected adults (age ≥25 years) with type 1 diabetes (A) <br /> Evidence for A1C-lowering less strong in children, teens, and younger adults; however, CGM may be helpful; success correlates with adherence to ongoing use of the device (C) <br /> CGM may be a supplemental tool to SMBG in those with hypoglycemia unawareness and/or frequent hypoglycemic episodes (E) <br /> Real-time CGM through the measurement of interstitial glucose (which correlates well with plasma glucose) is available; these sensors require calibration with SMBG; the latter are still recommended for making acute treatment decision and CGM devices have alarms for hypo- and hyperglycemic excursions <br /> A 26-week randomized trial of 322 type 1 patients showed that adults age 25 years and older using intensive insulin therapy and CGM experienced a 0.5% reduction in A1C (from ~7.6–7.1%) compared with usual intensive insulin therapy with SMBG2 <br /> Overall, meta-analyses suggests that compared with SMBG, CGM lowers A1C by ~0.26%3 <br />
  • Recommendations for A1C testing1 are summarized on this slide <br /> An A1C test should be performed at least two times a year in patients who are meeting their treatment goals and have stable glycemic control (E) <br /> In patients whose therapy has changed or who are not meeting glycemic goals, the A1C test should be performed quarterly (E); this helps determine whether a patient’s glycemic targets are being reached and maintained <br /> When needed for timely decisions on when to change therapy, point-of-care testing (POC) for A1C may be used (E) <br /> The A1C test is subject to certain limitations: conditions that affect erythrocyte turnover (e.g., hemolysis, blood loss) and hemoglobin variants must be considered, particularly when the A1C result does not correlate with the patient’s clinical situation;2 in addition, A1C does not provide a measure of glycemic variability or hypoglycemia <br /> For patients prone to glycemic variability (especially type 1 diabetic patients, or type 2 diabetic patients with severe insulin deficiency), glycemic control is best judged by the combination of result of self-monitoring of blood glucose (SMBG) testing and A1C <br /> The A1C may also serve as a check on the accuracy of a patient’s meter and adequacy of the SMBG testing schedule <br />
  • Table 8, as shown on this slide, contains the correlation between A1C levels and mean plasma glucose (PG) levels based on data from the international A1C-Derived Average Glucose (ADAG) trial using frequent SMBG and continuous glucose monitoring (CGM) in 507 adults (83% Caucasian) with type 1, type 2, and no diabetes1 <br /> The ADA and the American Association of Clinical Chemistry have determined that the correlation (r = 0.92) is strong enough to justify reporting both an A1C result and an estimated average glucose (eAG) results when a clinician orders the A1C test2 <br /> A calculator for converting A1C results into eAG, in either mg/dL or mmol/L, is available at http://professional.diabetes.org/eAG <br /> For patients in whom A1C/eAG and measured blood glucose appear discrepant, clinicians should consider the possibilities of hemoglobinopathy or altered red cell turnover, and the options of more frequent and/or different timing of SMBG or use of CGM <br /> Other measures of chronic glycemia, such as fructosamine, are available, but their linkage to average glucose and their prognostic significance are not as clear as is the case for A1C <br />
  • Glycemic control is fundamental to the management of diabetes; recommendations for glycemic goals in nonpregnant adults1 are reviewed on three slides <br /> Slide 1 of 3 <br /> Lowering A1C to below or around 7% has been shown to reduce microvascular complications of diabetes, and if implemented soon after the diagnosis of diabetes is associated with long-term reduction in macrovascular disease; therefore, a reasonable A1C goal for many nonpregnant adults is &lt;7% (B) <br /> The DCCT,2 a prospective RCT of intensive versus standard glycemic control in patients with relatively recently diagnosed type 1 diabetes, showed definitively that improved glycemic control is associated with significantly decreased rates of microvascular (retinopathy and nephropathy) and neuropathic complications <br /> Follow-up of the DCCT cohorts in the Epidemiology of Diabetes Interventions and Complications (EDIC) study3,4 demonstrated persistence of these microvascular benefits in previously intensively treated subjects, even though their glycemic control approximated that of previous standard arm subjects during follow-up <br />
  • Glycemic control is fundamental to the management of diabetes; recommendations for glycemic goals in nonpregnant adults are reviewed on three slides <br /> Slide 2 of 3 <br /> Providers might reasonably suggest more stringent A1C goals (such as &lt;6.5%) for selected individual patients, if this can be achieved without significant hypoglycemia or other adverse effects of treatment (C) <br /> Appropriate patients might include those with short duration of diabetes, long life expectancy, and no significant CVD (C) <br />
  • Glycemic control is fundamental to the management of diabetes; recommendations for glycemic goals in nonpregnant adults are reviewed on three slides <br /> Slide 3 of 3 <br /> Less-stringent A1C goals (such as &lt;8%) may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, and those with longstanding diabetes in whom the general goal is difficult to attain despite DSME, appropriate glucose monitoring, and effective doses of multiple glucose lowering agents including insulin (B) <br />
  • The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study randomized 10,251 participants with either history of a CVD event or significant CVD risk to a strategy of intensive glycemic control (target A1C 6.0%) or standard glycemic control (A1C target 7.0-7.9%); investigators used multiple glycemic medications in both arms <br /> From a baseline median A1C of 8.1%, the intensive arm reached a median A1C of 6.4% within 12 months of randomization; the standard group reached a median A1C of 7.5% <br /> The glycemic control arm of ACCORD was halted early due to the finding of an increased rate of mortality in the intensive arm compared with the standard arm (1.41% vs. 1.14% per year; HR 1.22 [95% CI 1.01 to 1.46]); with a similar increase in cardiovascular deaths <br /> The primary outcome of ACCORD (MI, stroke, or cardiovascular death) was lower in the intensive glycemic control group, due to a reduction in nonfatal MI, but this reduction was not statistically significant when the study was terminated1 <br /> The potential cause of excess deaths in the intensive group of the ACCORD has been difficult to pinpoint. Exploratory analyses of the mortality findings of ACCORD (evaluating variables including weight gain, use of any specific drug or drug combination, and hypoglycemia) were reportedly unable to identify a clear explanation for the excess mortality in the intensive arm. The ACCORD investigators subsequently published additional analyses showing no increase in mortality in the intensive arm participants who achieved A1C levels7% or in those who lowered their A1C quickly after trial enrollment <br /> In fact, the converse was observed—those at highest risk for mortality were participants in the intensive arm with the highest A1C levels <br />
  • The ADVANCE study of intensive versus standard glycemic control in type 2 diabetes found a statistically significant reduction in albuminuria with an A1C target of 6.5% (achieved median A1C 6.3%) compared with standard therapy achieving a median A1C of 7.0% (63) <br /> ADVANCE randomized participants to intensive glycemic control (with primary therapy being the sulfonylurea gliclazide and additional medications as needed to achieve a target A1C of 6.5%) or to standard therapy (in which any medication but gliclazide could be used and the glycemic target was according to “local guidelines”) <br /> Participants in ADVANCE were slightly older than those in ACCORD and VADT and had similar high CVD risk; however, they had an average duration of diabetes that was 2 years shorter, lower baseline A1C (median 7.2%), and almost no use of insulin at enrollment <br /> Median A1C levels achieved in the intensive and standard arms were 6.3 and 7.0%, respectively, and maximal separation between the arms took several years to achieve <br /> Use of other drugs that favorably impact CVD risk (aspirin, statins, and angiotensin enzyme inhibitors) was lower in ADVANCE than in ACCORD or VADT <br /> The primary outcome of ADVANCE was a combination of microvascular events (nephropathy and retinopathy) and major adverse cardiovascular events (MI, stroke, and cardiovascular death) <br /> Intensive glycemic control significantly reduced the primary end point, although this was due to a significant reduction in the microvascular outcome, primarily development of macroalbuminuria, with no significant reduction in the macrovascular outcome <br /> There was no difference in overall or cardiovascular mortality between the intensive compared with the standard glycemic control arms <br />
  • The Veterans Affairs Diabetes Trial (VADT) randomized participants with type 2 diabetes uncontrolled on insulin or maximal dose oral agents (median entry A1C 9.4%) to a strategy of intensive glycemic control (goal A1C 6.0%) or standard glycemic control, with a planned A1C separation of at least 1.5%1 <br /> Medication treatment algorithms were used to achieve the specified glycemic goals, with a goal of using similar medications in both groups; other CVD risk factors were treated aggressively and equally in both groups <br /> Median A1C levels of 6.9 and 8.4% were achieved in the intensive and standard arms, respectively, within the first year of the study; the primary outcome was a composite of CVD events; cumulative primary outcome was nonsignificantly lower in the intensive arm <br /> The evidence for a cardiovascular benefit of intensive glycemic control primarily rests on long-term follow-up of study cohorts treated early in the course of type 1 and type 2 diabetes and subset analyses of ACCORD, ADVANCE, and VADT. A recent group-level metaanalysis of the latter three trials suggests that glucose lowering has a modest (9%) but statistically significant reduction in major CVD outcomes, primarily nonfatal MI, with no significant effect on mortality <br /> A prespecified subgroup analysis suggested that major CVD outcome reduction occurred in patients without known CVD at baseline (HR 0.84 [95% CI 0.74–0.94]).2 Conversely, the mortality findings in ACCORD and subgroup analyses of VADT suggest that the potential risks of very intensive glycemic control may outweigh its benefits in some patients, such as those with very long duration of diabetes, known history of severe hypoglycemia, advanced atherosclerosis, and advanced age/frailty <br />
  • Recommended glycemic goals for many nonpregnant adults (Table 9)1 are shown on three slides <br /> Slide 1 of 3 <br /> These recommendations are based on those for A1C values, with listed blood glucose levels that appear to correlate with achievement of an A1C of &lt;7% <br /> The issue of preprandial versus postprandial self-monitoring of blood glucose (SMBG) is complex;2 in some epidemiological studies, elevated postchallenge two-hour oral glucose tolerance test (2-h OGTT) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose (FPG) <br /> In diabetic subjects, some surrogate measures of vascular pathology, such as endothelial dysfunction, are negatively affected by postprandial hyperglycemia3 <br />
  • Recommended glycemic goals for many nonpregnant adults (Table 9) are shown on three slides <br /> Slide 2 of 3 <br /> Glycemic goals should be individualized, based on a patient’s duration of diabetes, age, life expectancy, comorbid conditions, known cardiovascular disease (CVD) or advanced microvascular complications, unawareness of hypoglycemia, and other considerations <br />
  • Recommended glycemic goals for many nonpregnant adults (Table 9) are shown on three slides <br /> Slide 3 of 3 <br /> For individual patients, more or less stringent glycemic goals may be appropriate <br /> If A1C goals are not met despite reaching preprandial glucose goals, postprandial glucose may be targeted <br /> Postprandial hyperglycemia, like preprandial hyperglycemia, contributes to elevated A1C levels, with its relative contribution being higher at A1C levels that are closer to 7% <br /> However, outcome studies have clearly shown A1C to be the primary predictor of complications, and landmark trials such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) relied overwhelmingly on preprandial SMBG <br /> For individuals who have premeal glucose values within target but A1C values above target, monitoring postprandial plasma glucose 1-2 hours after the start of the meal and treatment aimed at reducing PPG values to &lt;180 mg/dL may help lower A1C <br />
  • Recommendations for insulin therapy for type 1 diabetes1 are shown on two slides <br /> Slide 1 of 2 <br /> Most people with type 1 diabetes should be treated with MDI injections (3–4 injections per day of basal and prandial insulin) or continuous subcutaneous insulin infusion (CSII)1 (A) <br /> The DCCT clearly showed that intensive insulin therapy was a key part of improved glycemia and better outcomes2,3 <br /> At the time of the study, therapy was carried out with short- and intermediate-acting human insulins <br /> Despite better microvascular outcomes, intensive insulin therapy was associated with a high rate in severe hypoglycemia (62 episodes per 100 patient-years of therapy) <br />
  • Recommendations for insulin therapy for type 1 diabetes1 are shown on two slides <br /> Slide 2 of 2 <br /> Most people with type 1 diabetes should use insulin analogs to reduce hypoglycemia risk (A) <br /> Consider screening those with type 1 diabetes for other autoimmune diseases (thyroid, vitamin B12 deficiency, celiac) as appropriate (B) <br /> Since the time of the DCCT, a number of rapid-acting and long-acting insulin analogs have been developed; these analogs are associated with less hypoglycemia with equal A1C lowering in type 1 diabetes2,3 <br />
  • Recommended pharmacological therapy for hyperglycemia in type 2 diabetes1 is summarized on three slides <br /> Slide 1 of 3 <br /> Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacological agent for type 2 diabetes (A) <br /> In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or A1C, consider insulin therapy, with or without additional agents, from theoutset (E) <br /> The ADA and EASD have recently partnered on guidance for individualization of use of medication classes and combinations in patients with type 2 diabetes2 <br /> This 2012 position statement is less prescriptive than prior algorithms and discusses advantages and disadvantages of the available medication classes and considerations for their use <br /> A patient-centered approach is stressed, taking into account patient preferences, cost and potential side effects of each class, effects on body weight, and hypoglycemia risk <br />
  • Recommended pharmacological therapy for hyperglycemia in type 2 diabetes1 is summarized on three slides <br /> Slide 2 of 3 <br /> If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain the A1C target over 3–6 months, add a second oral agent, a GLP-1 receptor agonist, or insulin (A) <br />
  • Recommended pharmacological therapy for hyperglycemia in type 2 diabetes1 is summarized on three slides <br /> Slide 3 of 3 <br /> A patient-centered approach should be used to guide choice of pharmacological agents; considerations include efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia risk, and patient preferences (E) <br /> Due to the progressive nature of type 2 diabetes, insulin therapy is eventually indicated for many patients with type 2 diabetes (B) <br />
  • The general recommendations for medical nutrition therapy (MNT)1 are included on this slide <br /> Individuals who have prediabetes or diabetes should receive individualized MNT as needed to achieve treatment goals, preferably provided by a registered dietitian familiar with the components of diabetes MNT (A) <br /> Because it can result in cost savings and improved outcomes (B), MNT should be covered by insurance and other payers (E) <br /> Although numerous studies have attempted to identify the optimal mix of macronutrients for meal plans of people with diabetes, it is unlikely that one such combination of macronutrients exists; the best mix of carbohydrates, protein, and fat appears to vary depending on individual circumstances <br /> MNT is an integral component of diabetes prevention, management, and self-management education <br /> In addition to its role in preventing and controlling diabetes, ADA recognizes the importance of nutrition as an essential component of an overall healthy lifestyle <br /> A full review of the evidence regarding nutrition in preventing and controlling diabetes and its complications and additional nutrition-related recommendations can be found in the ADA position statement “Nutrition Recommendations and Interventions for Diabetes,”2 which is being updated as of 2013 <br />
  • Look AHEAD (Action for HEAlth in Diabetes) is a large clinical trial designed to determine whether long-term weight loss will improve glycemia and prevent cardiovascular events in subjects with type 2 diabetes1 <br /> One-year results of the intensive lifestyle intervention in this trial show an average of 8.6% weight loss, significant reduction of A1C, and reduction in several cardiovascular disease (CVD) risk factors, with benefits sustained at 4 years2 <br /> At the time this article was going to press, the Look AHEAD trial was halted early, after 11 years of follow-up, because there was no significant difference in the primary cardiovascular outcome between the weight loss and standard care group (http://www.nih.gov/news/health/oct2012/niddk-19.htm) <br /> Multiple cardiovascular risk factors were improved with weight loss, and those participants on average were on fewer medications to achieve these improvements <br />
  • Recommendations for DSME1 are summarized on two slides <br /> Slide 1 of 2 <br /> People with diabetes should receive DSME according to national standards when their diabetes is diagnosed and as needed thereafter (B) <br /> Effective self-management and quality of life are the key outcomes of DSME and should be measured and monitored as part of care (C) <br /> DSME should address psychosocial issues, since emotional well-being is associated with positive diabetes outcomes (C) <br /> Diabetes self-management education (DSME) and diabetes self-management support (DSMS) are essential elements of diabetes care, and recently updated National Standards for Diabetes Self-Management Education and Support2 are based on evidence for its benefits <br /> Education helps people with diabetes initiate effective self-management and cope with diabetes when they are first diagnosed <br />
  • Recommendations for DSME1 are summarized on two slides <br /> Slide 2 of 2 <br /> DSME and DSMS programs are appropriate venues for people with prediabetes to receive education and support to develop and maintain behaviors that can prevent or delay the onset of diabetes (C) <br /> Because DSME can result in cost-savings and improved outcomes (B), DSME should be reimbursed by third-party payers (E) <br /> Ongoing diabetes self-management education (DSME) and diabetes self-management support (DSMS) also help people with diabetes maintain effective self-management throughout a lifetime of diabetes as they face new challenges and as treatment advances become available <br /> DSME helps patients optimize metabolic control, prevent and manage complications, and maximize quality of life in a cost-effective manner2 <br />
  • Exercise is an important part of the diabetes management plan <br /> Regular exercise has been shown to improve blood glucose control, reduce cardiovascular risk factors, contribute to weight loss, and improve well being1 <br /> Regular exercise may also prevent type 2 diabetes in high-risk individuals2-4 <br /> A joint position statement by ADA and the American College of Sports Medicine summarizes the evidence for the benefits of exercise in people with type 2 diabetes5 <br /> Recommendations for physical activity for people with diabetes1 are summarized on this slide <br /> People with diabetes should be advised to perform at least 150 minutes per week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate) (A) <br /> In the absence of contraindications, people with type 2 diabetes should be encouraged to perform resistance training three times per week (A) <br />
  • Psychological and social problems can impair the ability of the individual1-4 or the family to carry out diabetes care tasks and therefore compromise health status <br /> Opportunities exist for the clinician to assess psychosocial status in a timely and efficient manner so that referral for appropriate services can be accomplished <br /> Recommendations for psychosocial assessment and care5 are summarized on this slide <br /> Assessment of psychological and social situation should be included as an on-going part of the medical management of diabetes (E) <br /> Psychosocial screening and follow-up should include, but is not limited to, attitudes about the illness, expectations for medical management and outcomes, affect/mood, general and diabetes-related quality of life, resources (financial, social, and emotional), and psychiatric history (E) <br /> Screen for psychosocial problems such as depression and diabetes-related distress, anxiety, eating disorders, and cognitive impairment when self-management is poor (C) <br />
  • Hypoglycemia is the leading limiting factor in the glycemic management of patients with type 1 and insulin-treated type 2 diabetes1 <br /> Recommendations for treating hypoglycemia2 are summarized on three slides <br /> Slide 1 of 3 <br /> Individuals at risk for hypoglycemia should be asked about symptomatic and asymptomatic hypoglycemia at each encounter (C) <br /> Glucose (15-20 g) is the preferred treatment for the conscious individual with hypoglycemia, although any form of carbohydrate that contains glucose may be used (E) <br /> Glucagon should be prescribed for all individuals at significant risk of severe hypoglycemia, and caregivers or family members of these individuals should be instructed in its administration; glucagon administration is not limited to health care professionals (E) <br />
  • Recommendations for treating hypoglycemia1 are summarized on three slides <br /> Slide 2 of 3 <br /> Hypoglycemia unawareness or one or more episodes of severe hypoglycemia should trigger re-evaluation of the treatment regimen (E) <br /> Individuals with hypoglycemia unawareness or one or more episodes of severe hypoglycemia should be advised to raise their glycemic targets to strictly avoid further hypoglycemia for at least several weeks to reverse hypoglycemia unawareness (at least partially) and reduce risk of future episodes (B) <br />
  • Recommendations for treating hypoglycemia are summarized on three slides <br /> Slide 3 of 3 <br /> Ongoing assessment of cognitive function is suggested with increased vigilance for hypoglycemia by the clinician, patient, and caregivers if low cognition and/or declining cognition is found (B) <br />
  • Recommendations for patients for whom bariatric surgery may be an option as an effective weight loss treatment for severe obesity are summarized on this slide <br /> Bariatric surgery should be considered for adults with a body mass index (BMI) ≥35 kg/m2 and type 2 diabetes, especially if the diabetes or associated comorbidities are difficult to control with lifestyle and pharmacologic therapy (B) <br /> Patients with type 2 diabetes who have undergone bariatric surgery need life-long lifestyle support and medical monitoring (E) <br /> Although small trials have shown glycemic benefit of bariatric surgery in patients with type 2 diabetes and BMI of 30-35 kg/m2, there is currently insufficient evidence to recommend, in general, surgery in patients with BMI &lt;35 kg/m2 outside of a research protocol (E) <br /> The long-term benefits, cost-effectiveness, and risks of bariatric surgery in individuals with type 2 diabetes should be studied in well-designed, randomized controlled trials with optimal medical and lifestyle therapy as the comparator (E) <br />
  • Recommendations immunization in people with diabetes1 are summarized on two slides <br /> Slide 1 of 2 <br /> Influenza and pneumonia are common, preventable infectious diseases associated with high mortality and morbidity in the elderly and in people with chronic disease1 <br /> Although studies reporting the morbidity and mortality of influenza and pneumococcal pneumonia specifically in people with diabetes are limited, observational studies of patients with a variety of chronic illnesses, including diabetes, show that these conditions are associated with an increase in hospitalizations for influenza and its complications1 <br /> Safe and effective vaccines are available that can greatly reduce the risk of serious complications from these diseases1 <br /> Recommendations for the immunization of people with diabetes2 are summarized on this slide <br /> Annually provide an influenza vaccine to all diabetes patients ≥6 months of age (C) <br /> Administer pneumococcal polysaccharide vaccine to all diabetes patients ≥2 years of age; a one-time revaccination is recommended for individuals &gt;64 years of age previously immunized when they were &lt;65 years of age if the vaccine was administered &gt;5 years ago; other indications for repeat vaccination include nephrotic syndrome, chronic renal disease, and other immunocompromised states, such as after transplantation (C) <br />
  • Recommendations immunization in people with diabetes1 are summarized on two slides <br /> Slide 2 of 2 <br /> Administer hepatitis B vaccination to unvaccinated adults with diabetes who are aged 19 through 59 years (C) <br /> Consider administering hepatitis B vaccination to unvaccinated adults with diabetes who are aged ≥60 years (C) <br /> Late in 2012, the Advisory Committee on Immunization Practices of the CDC recommended that all previously unvaccinated adults with diabetes aged 19 through 59 years be vaccinated against hepatitis B virus (HBV) as soon as possible after a diagnosis of diabetes is made and that vaccination be considered for those aged ≥60 years, after assessing risk and likelihood of an adequate immune response (246) <br /> At least 29 outbreaks of HBV in long-term care facilities and hospitals have been reported to the CDC, with the majority involving adults with diabetes receiving “assisted blood glucose monitoring,” in which such monitoring is done by a health care professional with responsibility for more than one patient <br /> HBV is highly transmissible and stable for long periods of time on surfaces such as lancing devices and blood glucose meters, even when no blood is visible <br /> Blood sufficient to transmit the virus has also been found in the reservoirs of insulin pens, resulting in warnings against sharing such devices between patients <br />
  • Section VI. Prevention and Management of Diabetes Complications includes 43 slides(1 slide unless otherwise noted): <br /> Cardiovascular Disease (CVD) in Individuals with Diabetes <br /> Recommendations: Hypertension/Blood Pressure Control (6 slides) <br /> Recommendations: Dyslipidemia/Lipid Management (6 slides) <br /> Recommendations: Glycemic, Blood Pressure, Lipid Control in Adults <br /> Recommendations: Antiplatelet Agents (3 slides) <br /> Recommendations: Smoking Cessation <br /> Recommendations: Coronary Heart Disease Screening <br /> Recommendations: Coronary Heart Disease Treatment (2 slides) <br /> Recommendations: Nephropathy <br /> Recommendations: Nephropathy Screening <br /> Recommendations: Nephropathy Treatment (3 slides) <br /> Definitions of Abnormalities in Albumin Excretion <br /> Stages of Chronic Kidney Disease <br /> Management of CKD in Diabetes (2 slides) <br /> Recommendations: Retinopathy <br /> Recommendations: Retinopathy Screening (4 slides) <br /> Recommendations: Retinopathy Treatment (2 slides) <br /> Recommendations: Neuropathy Screening, Treatment (2 slides) <br /> Recommendations: Foot Care (4 slides) <br />
  • For those with diabetes, cardiovascular disease (CVD) is the major cause of morbidity and mortality and the largest contributor to the direct and indirect costs of diabetes1 <br /> Common conditions that coexist with type 2 diabetes, such as hypertension and dyslipidemia, are clear risk factors for CVD, and diabetes itself confers independent risk1 <br /> Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing of slowing CVD in people with diabetes1 <br /> Large benefits are seen when multiple risk factors are addressed globally2,3 <br /> There is evidence that measures of 10-year coronary heart disease (CHD) risk among U.S. adults with diabetes have improved significantly over the past decade4 <br />
  • Hypertension is a common comorbidity of diabetes that affects the majority of patients, with prevalence depending on type of diabetes, age, obesity, and ethnicity <br /> Hypertension is a major risk factor for both CVD and microvascular complications <br /> In type 1 diabetes, hypertension is often the result of underlying nephropathy, while in type 2 diabetes it usually coexists with other cardiometabolic risk factors <br /> This slide and the following five slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes <br /> Slide 1 of 6 – Screening and Diagnosis <br /> Blood pressure should be measured at every routine visit <br /> Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day (B) <br />
  • This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes <br /> Slide 2 of 6 – Goals <br /> People with diabetes and hypertension should be treated to a systolic blood pressure goal of &lt;140 mmHg. (B) <br /> Lower systolic targets, such as &lt;130 mmHg, may be appropriate for certain individuals, such as younger patients, if it can be achieved without undue treatment burden (C) <br /> Patients with diabetes should be treated to a diastolic blood pressure &lt;80 mmHg (B) <br />
  • This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes <br /> Slide 3 of 6 – Treatment (Slide 1 of 4) <br /> Patients with a blood pressure &gt;120/80 mmHg should be advised on lifestyle changes to reduce blood pressure (B) <br /> Patients with confirmed blood pressure ≥140/80 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals (B) <br />
  • This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes <br /> Slide 4 of 6 – Treatment (Slide 2 of 4) <br /> Lifestyle therapy for elevated blood pressure consists of weight loss if overweight, DASH-style dietary pattern including reducing sodium and increasing potassium intake, moderation of alcohol intake, and increased physical activity (B) <br />
  • This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes <br /> Slide 5 of 6 – Treatment (Slide 3 of 4) <br /> Pharmacologic therapy for patients with diabetes and hypertension should be paired with a regimen that included either an ACE inhibitor or an angiotensin II receptor blocker (ARB); if one class is not tolerated, the other should be substituted <br /> Multiple drug therapy (two or more agents at maximal doses) is generally required to achieve blood pressure targets (B) <br /> Administer one or more antihypertensive medications at bedtime (A) <br />
  • This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes <br /> Slide 6 of 6 – Treatment (Slide 4 of 4) <br /> If ACE inhibitors, angiotensin II receptor blockers (ARBs), or diuretics are used, serum creatine/estimated glomerular filtration rate (eGFR) and serum potassium levels should be monitored (E) <br /> In pregnant women with diabetes and chronic hypertension, blood pressure target goals of 110-129/65-79 mmHg are suggested in the interest of long-term maternal health and minimizing impaired fetal growth <br /> ACE inhibitors and angiotensin II receptor blockers (ARBs) are contraindicated during pregnancy (E) <br />
  • Patients with type 2 diabetes have an increased prevalence of lipid abnormalities, contributing to their high risk of CVD <br /> Low levels of HDL cholesterol, often associated with elevated triglyceride levels, are the most prevalent pattern of dyslipidemia in persons with type 2 diabetes <br /> This set of six slides summarize recommendations for screening, treatment, and goals for dyslipidemia/lipid management in patients with diabetes <br /> Slide 1 of 6 – Screening <br /> In most adult patients, measure fasting lipid profile at least annually (B) <br /> In adults with low-risk lipid values (LDL cholesterol &lt;100 mg/dl, HDL cholesterol &gt;50 mg/dl, and triglycerides &lt;150 mg/dl), lipid assessments may be repeated every 2 years (E) <br />
  • This set of six slides summarize recommendations for screening, treatment, and goals for dyslipidemia/lipid management in patients with diabetes <br /> Slide 2 of 6 – Treatment Recommendations and Goals (Slide 1 of 5) <br /> Lifestyle modification focusing on the reduction of saturated fat, trans fat, and cholesterol intake; increase of n-3 fatty acids, viscous fiber, and plant stanols/sterols; weight loss (if indicated) and increased physical activity should be recommended to improve the lipid profile in patients with diabetes (A) <br />
  • This set of six slides summarize recommendations for screening, treatment, and goals for dyslipidemia/lipid management in patients with diabetes <br /> Slide 3 of 6 – Treatment Recommendations and Goals (Slide 2 of 5) <br /> Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for diabetic patients <br /> With overt CVD (A) <br /> Without CVD who are over the age of 40 years and have one or more other CVD risk factors (A) <br /> For patients at lower risk (e.g., without overt CVD and younger than age 40 years), statin therapy should be considered in addition to lifestyle therapy if LDL cholesterol remains &gt;100 mg/dL or in those with multiple CVD risk factors (C) <br />
  • This set of six slides summarize recommendations for screening, treatment, and goals for dyslipidemia/lipid management in patients with diabetes <br /> Slide 4 of 6 – Treatment Recommendations and Goals (Slide 3 of 5) <br /> In individuals without overt CVD, the primary goal is an LDL cholesterol &lt;100 mg/dl(2.6 mmol/l) (A) <br /> In individuals with overt CVD, a lower LDL cholesterol goal of &lt;70 mg/dl (1.8 mmol/l), using a high dose of a statin, is an option (B) <br />
  • This set of six slides summarize recommendations for screening, treatment, and goals for dyslipidemia/lipid management in patients with diabetes <br /> Slide 5 of 6 – Treatment Recommendations and Goals (Slide 4 of 5) <br /> If drug-treated patients do not reach the targets outlined on the previous slide (Slide 3 of 5) on maximal tolerated statin therapy, a reduction in LDL cholesterol of ~30-40% from baseline is an alternative therapeutic goal (A) <br /> Triglyceride levels &lt;150 mg/dl (1.7 mmol/l) and HDL cholesterol &gt;40 mg/dl (1.0 mm/l) in men and &gt;50 mg/dl (1.3 mmol/l) in women, are desirable (C); however, LDL cholesterol-targeting statin therapy remains the preferred strategy (A) <br />
  • This set of six slides summarize recommendations for screening, treatment, and goals for dyslipidemia/lipid management in patients with diabetes <br /> Slide 6 of 6 – Treatment Recommendations and Goals (Slide 5 of 5) <br /> Combination therapy has been shown not to provide additional cardiovascular benefit above statin therapy alone and is not generally recommended (A) <br /> Statin therapy is contraindicated in pregnancy (B) <br />
  • This slide represents a summary of common treatment goals for A1C, blood pressure, and LDL cholesterol for most adults with diabetes <br />
  • Recommendations for the use of antiplatelet agents1 are summarized in three slides <br /> Slide 1 of 3 <br /> Low-dose (75–162 mg/day) aspirin use for primary prevention is reasonable for adults with diabetes and no previous history of vascular disease who are at increased CVD risk (10-year risk of CVD events &gt;10%) and who are not at increased risk for bleeding <br /> This generally includes most men over age 50 years and women over age 60 years who also have one or more of the following major risk factors: smoking, hypertension, dyslipidemia, family history of premature CVD, or albuminuria <br /> In 2010, a position statement of the ADA, AHA, and the American College of Cardiology Foundation (ACCF) updated prior joint recommendations for primary prevention2 <br />
  • Recommendations for the use of antiplatelet agents are summarized in three slides <br /> Slide 2 of 3 <br /> Aspirin should not be recommended for CVD prevention for adults with diabetes at low CVD risk (10-year CVD risk &lt;5%, such as in men &lt;50 and women &lt;60 years of age with no major additional CVD risk factors), since the potential adverse effects from bleeding likely offset the potential benefits (C) <br /> In patients in these age groups with multiple other risk factors (e.g., 10-year risk 5%-10%) clinical judgment is required (E) <br /> However, aspirin is no longer recommended for those at low CVD risk (women under age 60 years and men under age 50 years with no major CVD risk factors; 10-year CVD risk &lt;5%), as the low benefit is likely to be outweighed by the risks of significant bleeding <br /> Clinical judgment should be used for those at intermediate risk (younger patients with one or more risk factors, or older patients with no risk factors; those with 10-year CVD risk of 5–10%) until further research is available. Use of aspirin in patients under the age of 21 years is contraindicated due to the associated risk of Reye syndrome <br /> However, aspirin is no longer recommended for those at low CVD risk (women under age 60 years and men under age 50 years with no major CVD risk factors; 10-year CVD risk &lt;5%), as the low benefit is likely to be outweighed by the risks of significant bleeding <br /> Clinical judgment should be used for those at intermediate risk (younger patients with one or more risk factors, or older patients with no risk factors; those with 10-year CVD risk of 5–10%) until further research is available. Use of aspirin in patients under the age of 21 years is contraindicated due to the associated risk of Reye syndrome <br />
  • Recommendations for the use of antiplatelet agents1 are summarized in three slides <br /> Slide 3 of 3 <br /> Use aspirin therapy (75-162 mg/day) as a secondary prevention strategy in those with diabetes with a history of CVD (A) <br /> For patients with CVD and documented aspirin allergy, clopidogrel (75 mg/day) should be used (B) <br /> Combination therapy with ASA (75-162 mg/day) and clopidogrel (75 mg/day) is reasonable for up to a year after an acute coronary syndrome (B) <br /> Clopidogrel has been demonstrated to reduce CVD events in diabetic individuals2 <br /> It is recommended as adjunctive therapy in the first year after an acute coronary syndrome or as alternative therapy in aspirin-intolerant patients <br />
  • Recommendations for smoking cessation1 are summarized on this slide <br /> Advise all patients not to smoke or use tobacco products (A) <br /> Include smoking cessation counseling and other forms of treatment as a routine component of diabetes care (B) <br /> Smoking may have a role in the development of type 2 diabetes and other studies of individuals with diabetes consistently demonstrate that smokers have a heightened risk of CVD, premature death, and increased rate of microvascular complications of diabetes <br /> One study in smokers with newly diagnosed type 2 diabetes found smoking cessation was associated with amelioration of metabolic parameters and reduced blood pressure and albuminuria at 1 year2 <br /> The routine and thorough assessment of tobacco use is important as a means of preventing smoking or encouraging cessation <br /> A number of large randomized clinical trials have demonstrated the efficacy and cost-effectiveness of brief counseling in smoking cessation, including the use of quit lines, in the reduction of tobacco use. For the patient motivated to quit, the addition of pharmacological therapy to counseling is more effective than either treatment alone <br /> Special considerations should include assessment of level of nicotine dependence, which is associated with difficulty in quitting and relapse3 <br />
  • Recommendations for coronary heart disease (CHD) screening1 is summarized on this slide <br /> In asymptomatic patients, routine screening for coronary artery disease (CAD) is not recommended, as it does not improve outcomes as long as cardiovascular disease (CVD) risk factors are treated (A) <br /> Screening for CAD is reviewed in a recently updated consensus statement2 <br /> To identify the presence of CAD in diabetic patients without clear or suggestive symptoms, a risk factor-based approach to the initial diagnostic evaluation and subsequent follow-up has intuitive appeal <br /> However, recent studies concluded that using this approach fails to identify which patients with type 2 diabetes will have silent ischemia on screening tests3,4 <br />
  • Recommendations for the treatment of coronary heart disease1 are summarized on two slides <br /> Slide 1 of 2 <br /> In patients with known CVD, ACE inhibitor (C), aspirin (A), and statin therapy (A) (if not contraindicated) should be used to reduce the risk of cardiovascular events1 <br /> In patients with prior MI, β-blockers should be continued for at least 2 years postevent (B)1 <br /> In all patients with diabetes, cardiovascular risk factors should be assessed at least annually <br /> These risk factors include dyslipidemia, hypertension, smoking, a positive family history of premature coronary disease, and the presence of micro- or macroalbuminuria <br /> Abnormal risk factors should be treated as described elsewhere in these guidelines <br /> Patients at increased CHD risk should receive aspirin and a statin, and ACE inhibitor or ARB therapy if hypertensive, unless there are contraindications to a particular drug class <br /> Although clear benefit exists for ACE inhibitor and ARB therapy in patients with nephropathy or hypertension, the benefits in patients with CVD in the absence of these conditions is less clear, especially when LDL cholesterol is concomitantly controlled2,3 <br />
  • Recommendations for the treatment of coronary heart disease (CHD) are summarized on two slides <br /> Slide 2 of 2 <br /> Avoid thiazolidinedione (TZD) treatment in patients with symptomatic heart failure (C) <br /> Metformin may be used in patients with stable CHF if renal function is normal; it should be avoided in unstable or hospitalized patients with CHF (C) <br />
  • General recommendations for the care of patients with diabetes and nephropathy1 are summarized on this slide <br /> To reduce the risk or slow the progression of nephropathy, optimize glucose control (A) <br /> To reduce the risk or slow the progression of nephropathy, optimize blood pressure control (A) <br /> Diabetic nephropathy occurs in 20-40% of patients with diabetes and is the single leading cause of end-stage renal disease (ESRD) <br /> Persistent albuminuria in the range of 30-299 mg/24 h (historically called microalbuminuria) has been shown to be the earliest stage of diabetic nephropathy in type 1 diabetes and a marker for development of nephropathy in type 2 diabetes <br /> Microalbuminuria is also a well-established marker of increased CVD risk2,3 <br />
  • Recommendations for screening patients with diabetes for nephropathy are highlighted on this slide <br /> Perform an annual test to assess urine albumin excretion in type 1 diabetic patients with diabetes duration of 5 years and in all type 2 diabetic patients, starting at diagnosis (B) <br /> Measure serum creatinine at least annually in all adults with diabetes regardless of the degree of urine albumin excretion <br /> The serum creatinine should be used to estimate GFR and stage the level of chronic kidney disease (CKD), if present (E) <br />
  • Recommendations for the treatment of nephropathy in patients with diabetes1 are summarized in three slides <br /> Slide 1 of 3 <br /> Reduction of protein intake may improve measures of renal function (urine albumin excretion rate, GFR) (B) <br /> To 0.8 –1.0 g/kg body wt per day in those with diabetes, earlier stages of CKD <br /> To 0.8 g/kg body wt per day in later stages of CKD <br /> In the treatment of the nonpregnant patient with modestly elevated (30-299 mg/day) (C) or higher levels (≥399 mg/day) (A) of urinary albumin excretion, either ACE inhibitors or angiotensin II receptor blockers (ARBs) should be used (A) <br /> Intensive diabetes management with the goal of achieving near-normoglycemia has been shown in large prospective randomized studies to delay the onset and progression of increased urinary albumin excretion in patients with type 12 and type 23 diabetes <br /> The UKPDS provided strong evidence that control of blood pressure can reduce the development of nephropathy4 <br />
  • Recommendations for the treatment of nephropathy in patients with diabetes1 are summarized in three slides <br /> Slide 2 of 3 <br /> When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine (E) <br /> Continued monitoring of urine albumin excretion to assess both response to therapy and progression of disease is reasonable (E) <br /> When estimated GFR is &lt;60 mL/min/1.73 m2, evaluate and manage potential complications of CKD (E) <br /> ACE inhibitors have been shown to reduce major CVD outcomes (i.e., MI, stroke, death) in patients with diabetes,2 thus further supporting the use of these agents in patients with albuminuria, a CVD risk factor <br /> ARBs do not prevent onset of albuminuria in normotensive patients with type 1 or type 2 diabetes;3 however, ARBs have been shown to reduce the rate of progression from micro- to macroalbuminuria as well as ESRD in patients with type 2 diabetes4 <br />
  • Recommendations for the treatment of nephropathy in patients with diabetes are summarized in three slides <br /> Slide 3 of 3 <br /> Consider referral to a physician experienced in the care of kidney disease when there is uncertainty about the etiology of kidney disease (active urine sediment, absence of retinopathy, or rapid decline in GFR), difficult management issues, or advanced kidney disease (B) <br />
  • This table defines abnormalities of albumin excretion and the linkage between albumin-to-creatine ratio and 24-hour albumin excretion <br /> Because of variability in urinary albumin excretion, two of three specimens collected within a 3- to 6-month period should be abnormal before considering a patient to have developed increased urinary excretion or had a progression in albuminuria <br /> Exercise within 24 hours, infection, fever, CHF, marked hyperglycemia, and marked hypertension may elevate urinary albumin excretion over baseline values <br /> Historically, ratios between 30 and 299 have been called microalbuminuria and those 300 or greater have been called macroalbuminuria (or clinical albuminuria) <br />
  • The National Kidney Foundation classification of the stages of chronic kidney disease(Table 12;1 adapted from Levey et al2) is primarily based on GFR levels and therefore differs from other systems, in which staging is based primarily on urinary albumin excretion3 <br /> Studies have found decreased GFR in the absence of increased urine albumin excretion in a substantial percentage of adults with diabetes4 <br /> Serum creatinine should therefore be measured at least annually in all adults with diabetes, regardless of the degree of urine albumin excretion <br /> Serum creatinine should be used to estimate GFR and to stage the level of CKD, if present <br /> GFR calculators are available at http://www.nkdep.nih.gov/lab-evaluation/gfr-calculators.shtml <br />
  • Management of chronic kidney disease (CKD) is summarized in two slides1,2 <br /> Slide 1 of 2 <br /> Complications of kidney disease correlate with level of kidney function <br /> When the eGFR is &lt;60 mL/min/1.73 m2, screening for complications of CKD is indicated, as summarized on this slide (Table 13) <br /> Consider referral to a physician experienced in the care of kidney disease when there is uncertainty about the etiology of kidney disease (heavy proteinuria, active urine sediment, absence of retinopathy, rapid decline in GFR, resistant hypertension) <br /> Other triggers for referral may include difficult management issues (anemia, secondary hyperparathyroidism, metabolic bone disease, or electrolyte disturbance) or advanced kidney disease <br /> The threshold for referral may vary depending on the frequency with which a provider encounters diabetic patients with significant kidney disease <br /> Early vaccination against hepatitis B is indicated in patients likely to progress to end-stage kidney disease <br />
  • Management of chronic kidney disease (CKD) is summarized in two slides1,2 <br /> Slide 2 of 2 <br /> When the eGFR is &lt;60 mL/min/1.73 m2, screening for complications of CKD is indicated, as summarized on this slide (Table 13) <br /> Consultation with a nephrologist when stage 4 CKD develops has been found to reduce cost, improve quality of care, and keep people off dialysis longer3 <br /> However, nonrenal specialists should not delay educating their patients about the progressive nature of diabetic kidney disease; the renal preservation benefits of aggressive treatment of blood pressure, blood glucose, and hyperlipidemia; and the potential need for renal replacement therapy <br />
  • Recommendations for the care of patients with diabetes with respect to retinopathy1 are summarized on this slide <br /> To reduce the risk or slow the progression of retinopathy, optimize glycemic control (A) <br /> To reduce the risk or slow the progression of retinopathy, optimize blood pressure control (A) <br /> Diabetic retinopathy is a highly specific vascular complication of both type 1 and type 2 diabetes, with prevalence strongly related to duration of diabetes <br /> Diabetic retinopathy is the most frequent cause of new cases of blindness among adults aged 20–74 years <br /> Glaucoma, cataracts, and other disorders of the eye occur earlier and more frequently in people with diabetes <br /> In addition to duration of diabetes, other factors that increase the risk of, or are associated with, retinopathy include chronic hyperglycemia2, the presence of nephropathy3, and hypertension4 <br />
  • Results of eye examinations should be documented and transmitted to the referring health care professional <br /> Recommendations for the screening of retinopathy in patients with diabetes are summarized in four slides <br /> Slide 1 of 4 <br /> Adults and children aged 10 years or older with type 1 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist within 5 years after the onset of diabetes (B) <br /> Patients with type 2 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist shortly after the diagnosis of diabetes (B) <br /> Examinations should be performed by an ophthalmologist or optometrist who is knowledgeable and experienced in diagnosing the presence of diabetic retinopathy and is aware of its management <br />
  • Recommendations for the screening of retinopathy in patients with diabetes1 are summarized in four slides <br /> Slide 2 of 4 <br /> Subsequent examinations for type 1 and type 2 diabetic patients should be repeated annually by an ophthalmologist or optometrist (B) <br /> Less frequent exams (every 2-3 years) may be considered following one or more normal eye exams, if recommended by the eye care professional (B) <br /> Examinations will be required more frequently if retinopathy is progressing (B) <br /> Subsequent examinations for type 1 and type 2 diabetic patients are generally repeated annually <br /> Less frequent exams (every 2–3 years) may be cost effective after one or more normal eye exams, and in a population with well-controlled type 2 diabetes there was essentially norisk of development of significant retinopathy with a 3-year interval after a normal examination2 <br /> Examinations will be required more frequently if retinopathy is progressing3 <br />
  • Recommendations for the screening of retinopathy in patients with diabetes are summarized in four slides <br /> Slide 3 of 4 <br /> High-quality fundus photographs can detect most clinically significant diabetic retinopathy. Interpretation of the images should be performed by a trained eye care provider (E) <br /> While retinal photography may serve as a screening tool for retinopathy, it is not a substitute for a comprehensive eye exam, which should be performed at least initially and at intervals thereafter as recommended by an eye care professional (E) <br /> The use of retinal photography with remote reading by experts has great potential in areas where qualified eye care professionals are not available and may also enhance efficiency and reduce costs when the expertise of ophthalmologists can be utilized for more complex examinations and for therapy (378) <br /> In-person exams are still necessary when the photos are unacceptable and for follow-up of abnormalities detected <br /> Photos are not a substitute for a comprehensive eye exam, which should be performed at least initially and at intervals thereafter as recommended by an eye care professional <br /> Results of eye examinations should be documented and transmitted to the referring health care professional <br />
  • Recommendations for the screening of retinopathy in patients with diabetes are summarized in four slides <br /> Slide 4 of 4 <br /> Women with preexisting diabetes who are planning pregnancy or who have become pregnant should have a comprehensive eye examination and be counseled on the risk of development and/or progression of diabetic retinopathy (B) <br /> Eye examination should occur in the first trimester with close follow-up throughout pregnancy and for 1 year postpartum (B) <br />
  • Recommendations for the treatment of retinopathy in patients with diabetes are summarized in two slides <br /> Slide 1 of 2 <br /> Promptly refer patients with any level of macular edema, severe non-proliferative diabetic retinopathy (NPDR), or any peripheral diabetic retinopathy (PDR) to an ophthalmologist who is knowledgeable and experienced in the management and treatment of diabetic retinopathy (A) <br /> Laser photocoagulation therapy is indicated to reduce the risk of vision loss in patients with high-risk PDR, clinically significant macular edema, and in some cases of severe NPDR (A) <br />
  • Recommendations for the treatment of retinopathy in patients with diabetes are summarized in two slides <br /> Slide 2 of 2 <br /> Anti-vascular endothelial growth factor (VEGF) therapy is indicated for diabetic macular edema (A) <br /> The presence of retinopathy is not a contraindication to aspirin therapy for cardioprotection, as this therapy does not increase the risk of retinal hemorrhage (A) <br />
  • Recommendations for the screening and treatment of neuropathy in patients with diabetes are summarized in two slides <br /> Slide 1 of 2 <br /> All patients should be screened for distal symmetric polyneuropathy (DPN) at diagnosis and at least annually thereafter using simple clinical tests (B) <br /> Electrophysiological testing is rarely needed, except in situations where the clinical features are atypical (E) <br /> The diabetic neuropathies are heterogeneous with diverse clinical manifestations; they may be focal or diffuse <br /> Most common among the neuropathies are chronic sensorimotor diabetic peripheral neuropathy (DPN) and autonomic neuropathy; although DPN is a diagnosis of exclusion, complex investigations to exclude other conditions are rarely needed <br /> Early recognition and appropriate management of neuropathy in the patient with diabetes are important for a number of reasons: 1) nondiabetic neuropathies may be present in patients with diabetes and may be treatable; 2) a number of treatment options exist for symptomatic diabetic neuropathy; 3) up to 50% of DPN may be asymptomatic and patients are at risk of insensate injury to their feet; 4) autonomic neuropathy and particularly cardiovascular autonomic neuropathy is associated with substantial morbidity, mortality <br />
  • Recommendations for the screening and treatment of neuropathy in patients with diabetes1 are summarized in two slides <br /> Slide 2 of 2 <br /> Screening for signs and symptoms of cardiovascular autonomic neuropathy should be instituted at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes; special testing is rarely needed and may not affect management or outcomes (E) <br /> Medications for the relief of specific symptoms related to DPN and autonomic neuropathy are recommended, as they improve the quality of life of the patient (E) <br /> Specific treatment for the underlying nerve damage is not currently available, other than improved glycemic control, which may modestly slow progression2 but not reverse neuronal loss; effective symptomatic treatments are available for some manifestations of DPN3 and autonomic neuropathy <br />
  • Recommendations for foot care in patients with diabetes are summarized in four slides <br /> Slide 1 of 4 <br /> For all patients with diabetes, perform an annual comprehensive foot examination to identify risk factors predictive of ulcers and amputations <br /> The foot examination should include inspection, assessment of foot pulses, and testing for loss of protective sensation (LOPS) (10-g monofilament plus testing any one of: vibration using 128-Hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold) (B) <br /> Amputation and foot ulceration, consequences of diabetic neuropathy and/or peripheral artery disease (PAD), are common and major causes of morbidity and disability in people with diabetes; early recognition and management of risk factors can prevent or delay adverse outcomes <br /> Risk of ulcers or amputations is increased in people who have the following risk factors: <br /> Previous amputation <br /> Past foot ulcer history <br /> Peripheral neuropathy <br /> Foot deformity <br /> Peripheral vascular disease <br /> Visual impairment <br /> Diabetic nephropathy (especially patients on dialysis) <br /> Poor glycemic control <br /> Cigarette smoking <br />
  • Recommendations for foot care in patients with diabetes are summarized in four slides <br /> Slide 2 of 4 <br /> This slide illustrates how to perform the 10-g monofilament test1,2 <br />
  • Recommendations for foot care in patients with diabetes are summarized in four slides <br /> Slide 3 of 4 <br /> Provide general foot self-care education to all patients with diabetes (B) <br /> A multidisciplinary approach is recommended for individuals with foot ulcers and high-risk feet, especially those with a history of prior ulcer or amputation (B) <br /> Refer patients who smoke, have LOPS and structural abnormalities, or have history of prior lower-extremity complications to foot care specialists for ongoing preventive care and life-long surveillance (C) <br />
  • Recommendations for foot care in patients with diabetes are summarized in four slides <br /> Slide 4 of 4 <br /> Initial screening for peripheral arterial disease (PAD) should include a history for claudication and an assessment of the pedal pulses; consider obtaining an ankle-brachial index (ABI), as many patients with PAD are asymptomatic (C) <br /> Refer patients with significant claudication or a positive ABI for further vascular assessment and consider exercise, medications, and surgical options (C) <br /> Initial screening for PAD should include a history for claudication and an assessment of the pedal pulses <br /> A diagnostic ABI should be performed in any patient with symptoms of PAD <br /> Due to the high estimated prevalence of PAD in patients with diabetes and the fact that many patients with PAD are asymptomatic, an ADA consensus statement on PAD (386) suggested that a screening ABI be performed in patients over 50 years of age and be considered in patients under 50 years of age who have other PAD risk factors (e.g., smoking, hypertension, hyperlipidemia, or duration of diabetes &gt;10 years) <br /> Refer patients with significant symptoms or a positive ABI for further vascular assessment and consider exercise, medications, and surgical options (386) <br />
  • Section VII. Assessment of Common Comorbid Conditions includes 1 slide <br /> Recommendations: Assessment of Common Comorbid Conditions <br />
  • Patients who have risk factors, signs or symptoms of common diabetes-associated conditions should be assessed <br /> In addition to the commonly appreciated comorbidities of obesity, hypertension, and dyslipidemia, diabetes is also associated with other diseases or conditions at rates higher than those of age-matched people without diabetes <br /> A few of the more common comorbidities are described on this slide (Table 14) <br />
  • Section VIII. Diabetes Care in Specific Populations includes 20 slides (1 slide unless otherwise indicated): <br /> Recommendations: Pediatric Glycemic Control (Type 1 Diabetes) <br /> Recommendations: Pediatric Nephropathy (Type 1 Diabetes) <br /> Recommendations: Pediatric Hypertension (Type 1 Diabetes) (3 slides) <br /> Recommendations: Pediatric Dyslipidemia (Type 1 Diabetes) (4 slides) <br /> Recommendations: Pediatric Retinopathy (Type 1 Diabetes) <br /> Recommendations: Pediatric Celiac Disease (Type 1 Diabetes) (2 slides) <br /> Recommendations: Pediatric Hypothyroidism (Type 1 Diabetes) <br /> Recommendations: Transition from Pediatric to Adult Care <br /> Recommendations: Preconception Care (2 slides) <br /> Recommendations: Older Adults (2 slides) <br /> Recommendations: Cystic Fibrosis-Related Diabetes (CFRD) (2 slides) <br />
  • Recommendations for glycemic control in children with type 1 diabetes are summarized on this slide <br /> As is the case for all children, children with diabetes or prediabetes should be encouraged to engage in at least 60 minutes of physical activity each day (B) <br /> Clinicians should consider age when setting glycemic goals in children and adolescents with type 1 diabetes (E) <br /> Three-quarters of all cases of type 1 diabetes are diagnosed in individuals &lt;18 years of age <br /> While current standards for diabetes management reflect the need to maintain glucose control as near to normal as safely possible, special consideration should be given to the unique risks of hypoglycemia in young children <br /> Glycemic goals may need to be modified to take into account the fact that most children&lt;6 or 7 years of age have a form of “hypoglycemic unawareness,” including immaturity of and a relative inability to recognize and response to hypoglycemic symptoms, placing them at greater risk for severe hypoglycemia and its sequelae <br /> In addition, and unlike the case in adults, young children under the age of 5 years may be at risk for permanent cognitive impairment after episodes of severe hypoglycemia <br /> In selecting glycemic goals, the benefits on long-term health outcomes of achieving a lower A1C should be balanced against the risks of hypoglycemia and the developmental burdens of intensive regimens in children and youth <br />
  • Recommendations for pediatric nephropathy are summarized on this slide <br /> Annual screening for microalbuminuria, for albumin-to-creatinine (ACR) ratio, should be considered once the child is 10 years of age and has had diabetes for 5 years (E) <br /> Confirmed, persistently elevated ACR on two additional urine specimens from different days should be treated with an ACE inhibitor, titrated to normalization of albumin excretion if possible (E) <br />
  • Recommendations for the care of children and adolescents with hypertension are summarized in three slides <br /> Slide 1 of 3 <br /> Measure blood pressure (BP) at each routine visit; confirm high-normal BP or hypertension on a separate day (B) <br /> Treatment of high-normal blood pressure (systolic or diastolic blood pressure consistently above the 90th percentile for age, sex, and height) should include dietary intervention and exercise aimed at weight control and increased physical activity, if appropriate <br /> If target blood pressure is not reached with 3–6 months of lifestyle intervention, pharmacologic treatment should be initiated (E) <br /> It is important that blood pressure measurements are determined correctly, using the appropriate size cuff, and with the child seated and relaxed <br /> Hypertension should be confirmed on at least three separate days <br /> Normal blood pressure levels for age, sex, and height and appropriate methods for determinations are available online at www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf <br />
  • Recommendations for the care of children and adolescents with hypertension are summarized in three slides <br /> Slide 2 of 3 <br /> Pharmacologic treatment of hypertension (systolic or diastolic blood pressure consistently above the 95th percentile for age, sex, and height or consistently 130/80 mmHg, if 95% exceeds that value) should be initiated as soon as the diagnosis is confirmed (E) <br />
  • Recommendations for the care of children and adolescents with hypertension are summarized in three slides <br /> Slide 3 of 3 <br /> ACE inhibitors should be considered for the initial treatment of hypertension, following appropriate reproductive counseling due to potential teratogenic effects (E) <br /> The goal of treatment is a blood pressure consistently &lt;130/80 mmHg or below the 90th percentile for age, sex, and height, whichever is lower (E) <br />
  • Recommendations for the screening and treatment of children and adolescents with type 1 diabetes for dyslipidemia are summarized in four slides1 <br /> Slide 1 of 4 <br /> If there is a family history of hypercholesterolemia (total cholesterol 240 mg/dl) or a cardiovascular event before age 55 years, or if family history is unknown, then a fasting lipid profile should be performed on children 2 years of age soon after diagnosis (after glucose control has been established) <br /> People diagnosed with type 1 diabetes in childhood have a high risk of early subclinical2-4 and clinical5 CVD <br />
  • Recommendations for the screening and treatment of children and adolescents with type 1 diabetes for dyslipidemia are summarized in four slides <br /> Slide 2 of 4 <br /> If family history is not of concern, then the first lipid screening should be performed at puberty (≥10 years of age) (E) <br /> All children diagnosed with diabetes at or after puberty should have a fasting lipid profile performed soon after diagnosis (after glucose control has been established) (E) <br />
  • Recommendations for the screening and treatment of children and adolescents with type 1 diabetes for dyslipidemia are summarized in four slides <br /> Slide 3 of 4 <br /> For both age-groups, if lipids are abnormal, annual monitoring is recommended <br /> If LDL cholesterol values are within the accepted risk levels (100 mg/dL [2.6 mmol/L]), a lipid profile should be repeated every 5 years (E) <br />
  • Recommendations for the screening and treatment of children and adolescents with type 1 diabetes for dyslipidemia are summarized in four slides <br /> Slide 4 of 4 <br /> Initial therapy should consist of optimization of glucose control and MNT using a Step II AHA diet aimed at a decrease in the amount of saturated fat in the diet (E) <br /> After the age of 10 years, the addition of a statin is recommended in patients who, after MNT and lifestyle changes, have LDL cholesterol 160 mg/dL (4.1 mmol/L) or LDL cholesterol 130 mg/dl (3.4 mmol/L) and one or more CVD risk factors (E) <br /> The goal of therapy is an LDL cholesterol value 100 mg/dL (2.6 mmol/L) (E) <br />
  • Recommendations for those with type 1 diabetes and pediatric retinopathy1 are summarized on this slide <br /> The first ophthalmologic examination should be obtained once the child is 10 years of age and has had diabetes for 3-5 years (E) <br /> After the initial examination, annual routine follow-up is generally recommended; less frequent examinations may be acceptable on the advice of an eye care professional (E) <br /> Although retinopathy (like albuminuria) most commonly occurs after the onset of puberty and after 5–10 years of diabetes duration,2 it has been reported in prepubertal children and with diabetes duration of only 1–2 years <br /> Referrals should be made to eye care professionals with expertise in diabetic retinopathy, an understanding of the risk for retinopathy in the pediatric population, and experience in counseling the pediatric patient and family on the importance of early prevention/intervention <br />
  • Recommendations for the care of children with type 1 diabetes and celiac disease are summarized in two slides1 <br /> Slide 1 of 2 <br /> Children with type 1 diabetes should be screened for celiac disease by measuring tissue transglutaminase or anti-endomysial antibodies, with documentation of normal total serum IgA levels, soon after the diagnosis of diabetes (E) <br /> Testing should be repeated in children with growth failure, failure to gain weight, weight loss, diarrhea, flatulence, abdominal pain, or signs of malabsorption, or in children with frequent unexplained hypoglycemia or deterioration in glycemic control (E) <br /> Celiac disease is an immune-mediated disorder that occurs with increased frequency in patients with type 1 diabetes (1–16% of individuals compared with 0.3–1% in the general population)1,2 <br /> Symptoms of celiac disease include diarrhea, weight loss or poor weight gain, growth failure, abdominal pain, chronic fatigue, malnutrition due to malabsorption, other gastrointestinal problems, and unexplained hypoglycemia or erratic blood glucose concentrations3 <br /> Screening for celiac disease includes measuring serum levels of tissue transglutaminase or anti-endomysial antibodies, then small bowel biopsy in antibody positive children <br />
  • Recommendations for the care of children with type 1 diabetes and celiac disease are summarized in two slides <br /> Slide 2 of 2 <br /> Children with positive antibodies should be referred to a gastroenterologist for evaluation with endoscopy and biopsy (E) <br /> Children with biopsy-confirmed celiac disease should be placed on a gluten-free diet and have consultation with a dietitian experienced in managing both diabetes and celiac disease (B) <br />
  • Autoimmune thyroid disease is the most common autoimmune disorder associated with diabetes, occurring in 17-30% of patients with type 1 diabetes1 <br /> About one-quarter of children with type 1 diabetes have thyroid autoantibodies at the time of diagnosis;2 presence of these autoantibodies is predictive of thyroid dysfunction, generally hypothyroidism but less commonly hyperthyroidism3 <br /> Subclinical hypothyroidism may be associated with increased risk of symptomatic hypoglycemia4 and with reduced linear growth5 <br /> Hyperthyroidism alters glucose metabolism, potentially resulting in deterioration of metabolic control6 <br /> Children with type 1 diabetes should be screened for thyroid peroxidase and thyroglobulin antibodies at diagnosis (E) <br /> TSH concentrations should be measured after metabolic control has been established. If normal, they should be re-checked every 1–2 years, or if the patient develops symptoms of thyroid dysfunction, thyromegaly, or an abnormal growth rate (E) <br />
  • Care and close supervision of diabetes management is increasingly shifted from parents and other older adults throughout childhood and adolescence; however, the shift from pediatric to adult health care providers often occurs very abruptly as the older teen enters the next developmental stage, referred to as emerging adulthood,1 a critical period for young people who have diabetes <br /> Though scientific evidence continues to be limited, it is clear that early and ongoing attention be given to comprehensive coordinated planning for seamless transition of all youth from pediatric to adult health care2,3 <br /> A comprehensive discussion regarding the challenges faced during this period is found in the ADA position statement “Diabetes Care for Emerging Adults: Recommendations for the Transition from Pediatric to Adult Diabetes Care Systems”3 <br /> The National Diabetes Education Program (NDEP) has materials available to facilitate the transition process (http://ndep.nih.gov/transitions/) and The Endocrine Society (in collaboration with the ADA and other groups, has developed transition tools for clinicians and youth/families (http://www.endo-society.org/clinicalpractice/transition_of_care.cfm) <br /> This slide includes recommendations for transitioning teens with diabetes into adulthood4 <br />
  • Recommendations for the preconception care of women with diabetes are summarized in two slides <br /> Slide 1 of 2 <br /> A1C levels should be as close to normal as possible (7%) in an individual patient before conception is attempted (B) <br /> Starting at puberty, preconception counseling should be incorporated in the routine diabetes clinic visit for all women of child-bearing potential (C) <br /> Women with diabetes who are contemplating pregnancy should be evaluated and, if indicated, treated for diabetic retinopathy, nephropathy, neuropathy, and CVD (E) <br /> Major congenital malformations remain the leading cause of mortality and serious morbidity in infants of mothers with type 1 and type 2 diabetes <br /> Observational studies indicate that the risk of malformations increases continuously with increasing maternal glycemia during the first 6–8 weeks of gestation, as defined by first-trimester A1C concentrations <br /> There is no threshold for A1C values below which risk disappears entirely; however, malformation rates above the 1–2% background rate of nondiabetic pregnancies appear to be limited to pregnancies in which first-trimester A1C concentrations are &gt;1% above the normal range for a nondiabetic pregnant woman <br /> Preconception care of diabetes appears to reduce the risk of congenital malformations <br />
  • Recommendations for the preconception care of women with diabetes1 are summarized in two slides <br /> Slide 2 of 2 <br /> Medications used by such women should be evaluated prior to conception, since drugs commonly used to treat diabetes and its complications may be contraindicated or not recommended in pregnancy, including statins, ACE inhibitors, ARBs, and most noninsulin therapies (E) <br /> Since many pregnancies are unplanned, consider the potential risks and benefits of medications that are contraindicated in pregnancy in all women of childbearing potential, and counsel women using such medications accordingly (E) <br /> Women contemplating pregnancy need to be seen frequently by a multidisciplinary team experienced in the management of diabetes before and during pregnancy; among the oral antidiabetic agents, metformin and acarbose are classified as category B (no evidence of risk in humans) and all others as category C <br /> Potential risks and benefits of oral antidiabetic agents in the preconception period must be carefully weighed; data are insufficient to establish the safety of these agents in pregnancy <br /> For further discussion of preconception care, see the ADA’s consensus statement on pre-existing diabetes and pregnancy2 and the position statement3 on this subject <br />
  • Recommendations for the care of diabetes in older adults1 are summarized in two slides <br /> Slide 1 of 2 <br /> Older adults who are functional, are cognitively intact, and have significant life expectancy should receive diabetes care using goals developed for younger adults (E) <br /> Glycemic goals for older adults not meeting the above criteria may be related using individual criteria, but hyperglycemia leading to symptoms or risk of acute hyperglycemic complications should be avoid in all patients (E) <br /> Diabetes is an important health condition for the aging population; at least 20% of patients over the age of 65 years have diabetes, and this number can be expected to grow rapidly in the coming decades <br /> Older individuals with diabetes have higher rates of premature death, functional disability, and coexisting illnesses such as hypertension, CHD, and stroke than those without diabetes <br /> Older adults with diabetes are also at greater risk than other older adults for several common geriatric syndromes, such as polypharmacy, depression, cognitive impairment, urinary incontinence, injurious falls, and persistent pain <br /> A consensus report on diabetes and older adults2 have influenced these recommendations <br />
  • Recommendations for the care of diabetes in older adults1 are summarized in two slides <br /> Slide 2 of 2 <br /> Other cardiovascular risk factors should be treated in older adults with consideration of the time frame of benefit and the individual patient (E) <br /> Treatment of hypertension is indicated in virtually all older adults and lipid and aspirin therapy may benefit those with life expectancy at least equal to the time frame of primary or secondary prevention trials (E) <br /> Screening for diabetes complications should be individualized in older adults, but particular attention should be paid to complications that would lead to functional impairment (E) <br /> Although control of hyperglycemia may be important in older individuals with diabetes, greater reductions in morbidity and mortality may result from control of other cardiovascular risk factors rather than from tight glycemic control alone <br /> There is strong evidence from clinical trials of the value of treating hypertension in the elderly;2,3 there is less evidence for lipid-lowering and aspirin therapy, although the benefits of these interventions for primary and secondary prevention are likely to apply to older adults whose life expectancies equal or exceed the time frames seen in clinical trials <br />
  • Recommendations for the care of patients with cystic-fibrosis-related diabetes (CFRD) are summarized in two slides <br /> Slide 1 of 2 <br /> Annual screening for CFRD with OGTT should begin by age 10 years in all patients with cystic fibrosis who do not have CFRD (B) <br /> Use of A1C as a screening test for CFRD is not recommended (B) <br /> During a period of stable health, diagnosis of CFRD can be made in patients with cystic fibrosis according to usual diagnostic criteria <br /> CFRD is the most common comorbidity in persons with cystic fibrosis, occurring in about 20% of adolescents and 40–50% of adults <br /> The additional diagnosis of diabetes in this population is associated with worse nutritional status, more severe inflammatory lung disease, and greater mortality from respiratory failure <br /> Insulin insufficiency related to partial fibrotic destruction of the islet mass is the primary defect in CFRD; genetically determined function of the remaining β-cells and insulin resistance associated with infection and inflammation may also play a role <br />
  • Recommendations for the care of patients with cystic-fibrosis-related diabetes (CFRD)1 are summarized in two slides <br /> Slide 2 of 2 <br /> Patients with CFRD should be treated with insulin to attain individualized glycemic goals (A) <br /> Annual monitoring for complications of diabetes is recommended, beginning 5 years after the diagnosis of CFRD (E) <br /> Encouraging new data suggest early detection and aggressive insulin therapy have narrowed the gap in mortality between cystic fibrosis patients with and without diabetes, and have eliminated the sex difference in mortality2 <br /> Recommendations for the clinical management of CFRD can be found in a recent ADA position statement on this topic3 <br />
  • Section IX. Diabetes Care in Specific Settings includes eight slides: <br /> Recommendations: Diabetes Care in the Hospital (6 slides) <br /> Diabetes Care in the Hospital: NICE-SUGAR (2 slides) <br />
  • Recommendations for the care of patients with diabetes who are admitted to the hospital1 are summarized on six slides <br /> Slide 1 of 6 <br /> As noted on this slide, patients with diabetes admitted to the hospital should have their diabetes clearly identified in the medical record (E) and an order for blood glucose monitoring, with results available to all members of the health care team (E) <br /> Hyperglycemia in the hospital can represent previously known diabetes, previously undiagnosed diabetes, or hospital-related hyperglycemia (fasting blood glucose ≥126 mg/dL or random blood glucose ≥200 mg/dL occurring during the hospitalization that reverts to normal after hospital discharge) <br /> An updated consensus statement by the American Association of Clinical Endocrinologists (AACE) and ADA2 forms the basis for the information in this section <br /> The management of hyperglycemia in the hospital has often been considered secondary in importance to the condition that prompted admission3 <br /> However, a body of literature now supports targeted glucose control in the hospital setting for potential improved clinical outcomes <br />
  • Recommendations for the care of patients with diabetes who are admitted to the hospital are summarized on six slides <br /> Slide 2 of 6 <br /> Goals for blood glucose levels for critically ill patients are as follows: <br /> Critically Ill Patients <br /> Insulin therapy should be initiated for treatment of persistent hyperglycemia starting at a threshold of no greater than 180 mg/dL (10 mmol/L) <br /> Once insulin therapy is started, a glucose range of 140-180 mg/dL (7.8-10 mmol/L) is recommended for the majority of critically ill patients (A) <br /> More stringent goals, such as 110–140 mg/dL (6.1–7.8 mmol/L) may be appropriate for selected patients, as long as this can be achieved without significant hypoglycemia (C) <br /> Critically ill patients require an intravenous insulin protocol that has demonstrated efficacy and safety in achieving the desired glucose range without increasing risk for severe hypoglycemia (E) <br />
  • Recommendations for the care of patients with diabetes who are admitted to the hospital are summarized on six slides <br /> Slide 3 of 6 <br /> Goals for blood glucose levels for noncritically ill patients are as follows: <br /> Non-Critically Ill Patients <br /> There is no clear evidence for specific blood glucose goals <br /> If treated with insulin, premeal blood glucose target should generally be &lt;140 mg/dL (7.8 mmol/L) with random blood glucose &lt;180 mg/dL (10.0 mmol/L), provided these targets can be safely achieved <br /> More stringent targets may be appropriate in stable patients with previous tight glycemic control <br /> Less stringent targets may be appropriate in those with severe comorbidites (E) <br />
  • Recommendations for the care of patients with diabetes who are admitted to the hospital are summarized on six slides <br /> Slide 4 of 6 <br /> Scheduled subcutaneous insulin with basal, nutritional, and correction components isthe preferred method for achieving and maintaining glucose control in non-criticallyill patients (C) <br />
  • Recommendations for the care of patients with diabetes who are admitted to the hospital are summarized on six slides <br /> Slide 5 of 6 <br /> Glucose monitoring should be initiated in any patient not known to be diabetic who receives therapy associated with high risk for hyperglycemia, including high-dose glucocorticoid therapy, initiation of enteral or parenteral nutrition, or other medications such as octreotide or immunosuppressive medications (B) <br /> If hyperglycemia is documented and persistent, treatment is necessary; such patients should be treated to the same glycemic goals as patients with known diabetes (E) <br />
  • Recommendations for the care of patients with diabetes who are admitted to the hospital are summarized on six slides <br /> Slide 6 of 6 <br /> A plan for treating hypoglycemia should be established for each patient; episodes of hypoglycemia in the hospital should be tracked (E) <br /> All patients with diabetes admitted to the hospital should have an A1C obtained if the result of testing in the previous 2-3 months is not available (E) <br /> Patients with hyperglycemia in the hospital who do not have a diagnosis of diabetes should have appropriate plans for follow-up testing and care documented at discharge (E) <br />
  • Results of the NICE-SUGAR study1,2 are summarized on two slides <br /> Slide 1 of 2 <br /> Hyperglycemia in the hospital may result from stress; decompensation of type 1, type 2, or other forms of diabetes; and/or may be iatrogenic due to withholding of antihyperglycemic medications of administration of hyperglycemia-provoking agents such as glucocorticoids or vasopressors <br /> There is substantial observational evidence linking hyperglycemia in hospitalized patients (with or without diabetes) to poor outcomes <br /> The largest study to date, NICE-SUGAR, a multicenter, multinational randomized controlled trial, compared the effect of intensive glycemic control (target 81–108 mg/dL, mean blood glucose attained 115 mg/dL) to standard glycemic control (target 144– 180 mg/dL, mean blood glucose attained 144 mg/dL) on outcomes among 6,104 critically ill participants, almost all of whom required mechanical ventilation2 <br />
  • Results of the NICE-SUGAR study1,2 are summarized on two slides <br /> Slide 2 of 2 <br /> Ninety-day mortality was significantly higher in the intensive versus the conventional group in both surgical and medical patients, as was mortality from cardiovascular causes <br /> Severe hypoglycemia was also more common in the intensively treated group (6.8% vs 0.5%; P&lt;0.001); findings strongly suggest may it not be necessary to target blood glucose levels &lt;140 mg/dL; a highly stringent target of &lt;110 mg/dL may be dangerous <br /> In a recent meta-analysis of 26 trials (N=13,567) that included the NICE-SUGAR data, the pooled relative risk (RR) of death with intensive insulin therapy was 0.93 vs conventional therapy (95% CI 0.83–1.04)3 <br /> Approximately half of these trials reported hypoglycemia, with a pooled RR of intensive therapy of 6.0 (95% CI 4.5–8.0) <br /> The specific ICU setting influenced the findings; patients in surgical ICUs appearing to benefit from intensive insulin therapy (RR 0.63, 95% CI 0.44–0.91), while those in other medical and mixed critical care settings did not <br /> Overall, intensive insulin therapy appeared to increase risk of hypoglycemia but provided no overall benefit on mortality in the critically ill, although a possible mortality benefit to patients admitted to the surgical ICU was suggested <br />
  • Section X. Strategies for Improving Diabetes Care includes five slides: <br /> Recommendations: Strategies for Improving Diabetes Care (two slides) <br /> Objective 1: Optimize Provider and Team Behavior <br /> Objective 2: Support Patient Behavior Change <br /> Objective 3: Change the System of Care <br />
  • Recommendations: Strategies for Improving Care1 are summarized on two slides <br /> Slide 1 of 2 <br /> The Chronic Care Model (CCM) has been shown in numerous studies to be an effective framework for improving the quality of diabetes care2 <br /> The CCM includes six core elements for the provision of optimal care of patients with chronic disease <br /> 1) delivery system design (moving from a reactive to a proactive care delivery system where planned visits are coordinated through a team based approach) <br /> 2) self-management support <br /> 3) decision support (basing care on evidence-based, effective care guidelines) <br /> 4) clinical information systems (using registries that can provide patient-specific and population-based support to the care team) <br /> 5) community resources and policies (identifying or developing resources to support healthy lifestyles) <br /> 6) health systems (to create a quality-oriented culture) <br /> Redefinition of the roles of the clinic staff and promoting self-management on the part of the patient are fundamental to the successful implementation of the CCM3 <br />
  • Recommendations: Strategies for Improving Care1 are summarized on two slides <br /> Slide 2 of 2 <br /> In addition to timely treatment decisions that adhere to evidence-based guidelines, such treatment should be tailored to individual patient preferences, prognoses, and comorbidities <br /> A patient-centered communication style should be used that incorporates patient preferences, assesses literary and numeracy, and addresses any cultural barriers to care <br />
  • NDEP maintains an online resource (www.betterdiabetescare.nih.gov) to help health care professionals design and implement more effective health care delivery systems for those with diabetes <br /> Three specific objectives that outline practical strategies to achieve each are included on this and the next two slides <br /> Objective 1 <br /> Optimize provider and team behavior: the care team should prioritize timely and appropriate intensification of lifestyle and/or pharmaceutical therapy of patients who have not achieved beneficial levels of blood pressure, lipid, or glucose control1 <br /> As outlined on this slide, the following strategies each have been shown to optimize provider and team behavior and thereby catalyze reduction in A1C, blood pressure, and LDL cholesterol2 <br /> Explicit goal setting with patients <br /> Identifying and addressing language, numeracy, or cultural barriers to care <br /> Integrating evidence-based guidelines and clinical information tools into the process of care; and <br /> Incorporating care management teams including nurses, pharmacists, and other providers <br />
  • Objective 2 <br /> In addition to the approaches on this slide1, support for patient behavior change includes: <br /> Delivery of high-quality DSME, which has been shown to improve patient self-management, satisfaction, and glucose control2,3 <br /> Delivery of ongoing diabetes self-management support (DSMS) to ensure that gains achieved during DSME are sustained4-6 <br /> National DSME standards call for an integrated approach that includes clinical content and skills and behavioral strategies (goal-setting, problem solving), and addresses emotional concerns in each needed curriculum content area <br />
  • Objective 3 <br /> Change the system of care: additional strategies are outlined on this slide1 <br /> The most successful practices have an institutional priority for providing high quality of care2 <br /> Recent initiatives such as the Patient Centered Medical Home show promise to improve outcomes through coordinated primary care and offer new opportunities for team-based chronic disease care3 <br /> Alterations in reimbursement that reward the provision of appropriate and high quality care rather than visit-based billing,4 and that can accommodate the need to personalize care goals, may provide additional incentives to improve diabetes care5 <br /> It is clear that optimal diabetes management requires an organized, systematic approach and involvement of a coordinated team of dedicated health care professionals working in an environment where patient-centered high quality care is a priority <br />

Ada standards of medical care 2013 final 21 dec 2012 (2) Presentation Transcript

  • 1. STANDARDS OF MEDICAL CARESTANDARDS OF MEDICAL CARE IN DIABETES—2013IN DIABETES—2013
  • 2. Table of ContentsTable of Contents SectionSection Slide No.Slide No. ADA Evidence Grading System of Clinical Recommendations 3 I. Classification and Diagnosis 4-11 II. Testing for Diabetes in Asymptomatic Patients 12-15 III. Detection and Diagnosis of Gestational Diabetes Mellitus (GDM) 16-19 IV. Prevention/Delay of Type 2 Diabetes 20-22 V. Diabetes Care 23-64 VI. Prevention and Management of Diabetes Complications 65-108 VII. Assessment of Common Comorbid Conditions 109-110 VIII. Diabetes Care in Specific Populations 111-131 IX. Diabetes Care in Specific Settings 132-140 X. Strategies for Improving Diabetes Care 141-146
  • 3. ADA Evidence Grading System forADA Evidence Grading System for Clinical RecommendationsClinical Recommendations Level ofLevel of EvidenceEvidence DescriptionDescription A Clear or supportive evidence from adequately powered well-conducted, generalizable, randomized controlled trials Compelling nonexperimental evidence B Supportive evidence from well-conducted cohort studies or case-control study C Supportive evidence from poorly controlled or uncontrolled studies Conflicting evidence with the weight of evidence supporting the recommendation E Expert consensus or clinical experience ADA. Diabetes Care 2013;36(suppl 1):S12; Table 1.
  • 4. I. CLASSIFICATION AND DIAGNOSIS
  • 5. Classification of DiabetesClassification of Diabetes • Type 1 diabetes – β-cell destruction • Type 2 diabetes – Progressive insulin secretory defect • Other specific types of diabetes – Genetic defects in β-cell function, insulin action – Diseases of the exocrine pancreas – Drug- or chemical-induced • Gestational diabetes mellitus (GDM) ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S11.
  • 6. Criteria for the Diagnosis of DiabetesCriteria for the Diagnosis of Diabetes A1C ≥6.5% OR Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) OR 2-h plasma glucose ≥200 mg/dL (11.1 mmol/L) during an OGTT OR A random plasma glucose ≥200 mg/dL (11.1 mmol/L) ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S13; Table 2.
  • 7. Criteria for the Diagnosis of DiabetesCriteria for the Diagnosis of Diabetes A1C ≥6.5% The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay* *In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing. ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S13; Table 2.
  • 8. Criteria for the Diagnosis of DiabetesCriteria for the Diagnosis of Diabetes Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) Fasting is defined as no caloric intake for at least 8 h* *In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing. ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S13; Table 2.
  • 9. Criteria for the Diagnosis of DiabetesCriteria for the Diagnosis of Diabetes 2-h plasma glucose ≥200 mg/dL (11.1 mmol/L) during an OGTT The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water* *In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing. ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S13; Table 2.
  • 10. Criteria for the Diagnosis of DiabetesCriteria for the Diagnosis of Diabetes In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L) ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S13; Table 2.
  • 11. Prediabetes: IFG, IGT, Increased A1CPrediabetes: IFG, IGT, Increased A1C Categories of increased risk for diabetes (prediabetes)* FPG 100–125 mg/dL (5.6–6.9 mmol/L): IFG OR 2-h plasma glucose in the 75-g OGTT 140–199 mg/dL (7.8–11.0 mmol/L): IGT OR A1C 5.7–6.4% *For all three tests, risk is continuous, extending below the lower limit of a range and becoming disproportionately greater at higher ends of the range. ADA. I. Classification and Diagnosis. Diabetes Care 2013;36(suppl 1):S13; Table 3.
  • 12. II. TESTING FOR DIABETES INII. TESTING FOR DIABETES IN ASYMPTOMATIC PATIENTSASYMPTOMATIC PATIENTS
  • 13. Recommendations: Testing forRecommendations: Testing for Diabetes in Asymptomatic PatientsDiabetes in Asymptomatic Patients • Consider testing overweight/obese adults (BMI ≥25 kg/m2 ) and who have one or more additional risk factors – In those without risk factors, begin testing at age 45 years (B) • If tests are normal – Repeat testing at least at 3-year intervals (E) • Use A1C, FPG, or 2-h 75-g OGTT (B) • In those with prediabetes – Identify and, if appropriate, treat other CVD risk factors (B) ADA. II. Testing for Diabetes in Asymptomatic Patients. Diabetes Care 2013;36(suppl 1):S13.
  • 14. Criteria for Testing for Diabetes inCriteria for Testing for Diabetes in Asymptomatic Adult Individuals (1)Asymptomatic Adult Individuals (1) •Physical inactivity •First-degree relative with diabetes •High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander) •Women who delivered a baby weighing >9 lb or were diagnosed with GDM •Hypertension (≥140/90 mmHg or on therapy for hypertension) • HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 mmol/L) • Women with polycystic ovary syndrome (PCOS) • A1C ≥5.7%, IGT, or IFG on previous testing • Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans) • History of CVD *At-risk BMI may be lower in some ethnic groups. 1. Testing should be considered in all adults who are overweight (BMI ≥25 kg/m2 *) and have additional risk factors: ADA. Testing for Diabetes in Asymptomatic Patients. Diabetes Care 2013;36(suppl 1):S14; Table 4.
  • 15. 2. In the absence of criteria (risk factors on previous slide), testing for diabetes should begin at age 45 years 3. If results are normal, testing should be repeated at least at 3-year intervals, with consideration of more frequent testing depending on initial results (e.g., those with prediabetes should be tested yearly), and risk status ADA. Testing for Diabetes in Asymptomatic Patients. Diabetes Care 2013;36(suppl 1):S14; Table 4. Criteria for Testing for Diabetes inCriteria for Testing for Diabetes in Asymptomatic Adult Individuals (2)Asymptomatic Adult Individuals (2)
  • 16. III. DETECTION ANDIII. DETECTION AND DIAGNOSIS OFDIAGNOSIS OF GESTATIONAL DIABETESGESTATIONAL DIABETES MELLITUS (GDM)MELLITUS (GDM)
  • 17. Recommendations:Recommendations: Detection and Diagnosis of GDM (1)Detection and Diagnosis of GDM (1) • Screen for undiagnosed type 2 diabetes at the first prenatal visit in those with risk factors, using standard diagnostic criteria (B) • In pregnant women not previously known to have diabetes, screen for GDM at 24–28 weeks’ gestation, using a 75-g OGTT and specific diagnostic cut points (B) ADA. III. Detection and Diagnosis of GDM. Diabetes Care 2013;36(suppl 1):S15.
  • 18. Recommendations:Recommendations: Detection and Diagnosis of GDM (2)Detection and Diagnosis of GDM (2) • Screen women with GDM for persistent diabetes at 6–12 weeks postpartum, using OGTT, nonpregnancy diagnostic criteria (E) • Women with a history of GDM should have lifelong screening for the development of diabetes or prediabetes at least every 3 years (B) • Women with a history of GDM found to have prediabetes should receive lifestyle interventions or metformin to prevent diabetes (A) ADA. III. Detection and Diagnosis of GDM. Diabetes Care 2013;36(suppl 1):S15.
  • 19. Screening for and Diagnosis of GDMScreening for and Diagnosis of GDM • Perform a 75-g OGTT, with plasma glucose measurement fasting and at 1 and 2 h, at 24–28 weeks of gestation in women not previously diagnosed with overt diabetes • Perform OGTT in the morning after an overnight fast of at least 8 h • GDM diagnosis: when any of the following plasma glucose values are exceeded – Fasting ≥92 mg/dL (5.1 mmol/L) – 1 h ≥180 mg/dL (10.0 mmol/L) – 2 h ≥153 mg/dL (8.5 mmol/L) ADA. III. Detection and Diagnosis of GDM. Diabetes Care 2013;36(suppl 1):S15; Table 6.
  • 20. IV. PREVENTION/DELAY OFIV. PREVENTION/DELAY OF TYPE 2 DIABETESTYPE 2 DIABETES
  • 21. Recommendations:Recommendations: Prevention/Delay of Type 2 DiabetesPrevention/Delay of Type 2 Diabetes • Refer patients with IGT (A), IFG (E), or A1C 5.7–6.4% (E) to ongoing support program – Targeting weight loss of 7% of body weight – At least 150 min/week moderate physical activity • Follow-up counseling important for success (B) • Based on cost-effectiveness of diabetes prevention, third-party payers should cover such programs (E) ADA. IV. Prevention/Delay of Type 2 Diabetes. Diabetes Care 2013;36(suppl 1):S16.
  • 22. Recommendations:Recommendations: Prevention/Delay of Type 2 DiabetesPrevention/Delay of Type 2 Diabetes • Consider metformin for prevention of type 2 diabetes if IGT (A), IFG (E), or A1C 5.7–6.4% (E) – Especially for those with BMI >35 kg/m2 , age <60 years, and women with prior GDM (A) • In those with prediabetes, monitor for development of diabetes annually (E) • Screen for and treat modifiable risk factors for CVD (B) ADA. IV. Prevention/Delay of Type 2 Diabetes. Diabetes Care 2013;36(suppl 1):S16.
  • 23. V. DIABETES CARE
  • 24. • A complete medical evaluation should be performed to – Classify the diabetes – Detect presence of diabetes complications – Review previous treatment, risk factor control in patients with established diabetes – Assist in formulating a management plan – Provide a basis for continuing care • Perform laboratory tests necessary to evaluate each patient’s medical condition Diabetes Care: Initial EvaluationDiabetes Care: Initial Evaluation ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S16.
  • 25. Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (1)Diabetes Evaluation (1) Medical history (1) • Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic laboratory finding) • Eating patterns, physical activity habits, nutritional status, and weight history; growth and development in children and adolescents •Diabetes education history • Review of previous treatment regimens and response to therapy (A1C records) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7.
  • 26. Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (2)Diabetes Evaluation (2) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7. Medical history (2) • Current treatment of diabetes, including medications, medication adherence and barriers thereto, meal plan, physical activity patterns, and readiness for behavior change • Results of glucose monitoring and patient’s use of data • DKA frequency, severity, and cause • Hypoglycemic episodes – Hypoglycemia awareness – Any severe hypoglycemia: frequency and cause
  • 27. Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (3)Diabetes Evaluation (3) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7. Medical history (3) • History of diabetes-related complications – Microvascular: retinopathy, nephropathy, neuropathy • Sensory neuropathy, including history of foot lesions • Autonomic neuropathy, including sexual dysfunction and gastroparesis – Macrovascular: CHD, cerebrovascular disease, PAD – Other: psychosocial problems* , dental disease* *See appropriate referrals for these categories.
  • 28. Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (4)Diabetes Evaluation (4) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7. Physical examination (1) •Height, weight, BMI • Blood pressure determination, including orthostatic measurements when indicated •Fundoscopic examination* •Thyroid palpation • Skin examination (for acanthosis nigricans and insulin injection sites) *See appropriate referrals for these categories.
  • 29. Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (5)Diabetes Evaluation (5) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7. Physical examination (2) • Comprehensive foot examination –Inspection – Palpation of dorsalis pedis and posterior tibial pulses – Presence/absence of patellar and Achilles reflexes – Determination of proprioception, vibration, and monofilament sensation
  • 30. Laboratory evaluation • A1C, if results not available within past 2–3 months • If not performed/available within past year – Fasting lipid profile, including total, LDL, and HDL cholesterol and triglycerides – Liver function tests – Test for urine albumin excretion with spot urine albumin-to-creatinine ratio – Serum creatinine and calculated GFR – Thyroid-stimulating hormone in type 1 diabetes, dyslipidemia, or women over age 50 years Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (6)Diabetes Evaluation (6) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7.
  • 31. Referrals •Eye care professional for annual dilated eye exam •Family planning for women of reproductive age •Registered dietitian for MNT •Diabetes self-management education • Dentist for comprehensive periodontal examination • Mental health professional, if needed ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17; Table 7. Components of the ComprehensiveComponents of the Comprehensive Diabetes Evaluation (7)Diabetes Evaluation (7)
  • 32. ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17. Diabetes Care: ManagementDiabetes Care: Management • People with diabetes should receive medical care from a team that may include – Physicians, nurse practitioners, physician’s assistants, nurses, dietitians, pharmacists, mental health professionals – In this collaborative and integrated team approach, essential that individuals with diabetes assume an active role in their care • Management plan should recognize diabetes self- management education (DSME) and on-going diabetes support
  • 33. ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17. Diabetes Care: Glycemic ControlDiabetes Care: Glycemic Control • Two primary techniques available for health providers and patients to assess effectiveness of management plan on glycemic control – Patient self-monitoring of blood glucose (SMBG), or interstitial glucose – A1C
  • 34. Recommendations:Recommendations: Glucose Monitoring (1)Glucose Monitoring (1) • Patients on multiple-dose insulin (MDI) or insulin pump therapy should do SMBG (B) – At least prior to meals and snacks – Occasionally postprandially – At bedtime – Prior to exercise – When they suspect low blood glucose – After treating low blood glucose until they are normoglycemic – Prior to critical tasks such as driving ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17.
  • 35. Recommendations:Recommendations: Glucose Monitoring (2)Glucose Monitoring (2) • When prescribed as part of a broader educational context, SMBG results may be helpful to guide treatment decisions and/or patient self- management for patients using less frequent insulin injections or noninsulin therapies (E) • When prescribing SMBG, ensure that patients receive ongoing instruction and regular evaluation of SMBG technique and SMBG results, as well as their ability to use SMBG data to adjust therapy (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S16.
  • 36. Recommendations:Recommendations: Glucose Monitoring (3)Glucose Monitoring (3) • Continuous glucose monitoring (CGM) with intensive insulin regimens useful tool to lower A1C in selected adults (age ≥25 years) with type 1 diabetes (A) • Evidence for A1C-lowering less strong in children, teens, and younger adults; however, CGM may be helpful; success correlates with adherence to device use (C) • CGM may be a supplemental tool to SMBG in those with hypoglycemia unawareness and/or frequent hypoglycemic episodes (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S17-S18.
  • 37. Recommendations: A1CRecommendations: A1C • Perform A1C test at least twice yearly in patients meeting treatment goals (and have stable glycemic control) (E) • Perform A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals (E) • Use of point-of-care (POC) testing for A1C provides the opportunity for more timely treatment changes (E) ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S18.
  • 38. Correlation of A1C withCorrelation of A1C with Average Glucose (AG)Average Glucose (AG) Mean plasma glucose A1C (%) mg/dL mmol/L 6 126 7.0 7 154 8.6 8 183 10.2 9 212 11.8 10 240 13.4 11 269 14.9 12 298 16.5 ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S19; Table 8. These estimates are based on ADAG data of ~2,700 glucose measurements over 3 months per A1C measurement in 507 adults with type 1, type 2, and no diabetes. The correlation between A1C and average glucose was 0.92. A calculator for converting A1C results into estimated average glucose (eAG), in either mg/dL or mmol/L, is available at http://professional.diabetes.org/eAG.
  • 39. • Lowering A1C to below or around 7% has been shown to reduce microvascular complications and, if implemented soon after the diagnosis of diabetes, is associated with long-term reduction in macrovascular disease (B) • Therefore, a reasonable A1C goal for many nonpregnant adults is <7% (B) Recommendations:Recommendations: Glycemic Goals in Adults (1)Glycemic Goals in Adults (1) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S19.
  • 40. • Providers might reasonably suggest more stringent A1C goals (such as <6.5%) for selected individual patients, if this can be achieved without significant hypoglycemia or other adverse effects of treatment (C) • Appropriate patients might include those with short duration of diabetes, long life expectancy, and no significant CVD (C) Recommendations:Recommendations: Glycemic Goals in Adults (2)Glycemic Goals in Adults (2) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S19.
  • 41. Recommendations:Recommendations: Glycemic Goals in Adults (3)Glycemic Goals in Adults (3) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S19. • Less stringent A1C goals (such as <8%) may be appropriate for patients with (B) –History of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions –Those with longstanding diabetes in whom the general goal is difficult to attain despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose lowering agents including insulin
  • 42. Intensive Glycemic Control andIntensive Glycemic Control and Cardiovascular Outcomes: ACCORDCardiovascular Outcomes: ACCORD Gerstein HC, et al, for the Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:2545-2559. ©2008 New England Journal of Medicine. Used with permission. Primary Outcome: Nonfatal MI, nonfatal stroke, CVD death HR=0.90 (0.78-1.04)
  • 43. Intensive Glycemic Control andIntensive Glycemic Control and Cardiovascular Outcomes: ADVANCECardiovascular Outcomes: ADVANCE ©2008 New England Journal of Medicine. Used with permission. Primary Outcome: Microvascular plus macrovascular (nonfatal MI, nonfatal stroke, CVD death) Patel A, et al,. for the ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-2572. HR=0.90 (0.82-0.98)
  • 44. Intensive Glycemic Control andIntensive Glycemic Control and Cardiovascular Outcomes: VADTCardiovascular Outcomes: VADT Duckworth W, et al., for the VADT Investigators. N Engl J Med 2009;360:129-139. Primary Outcome: Nonfatal MI, nonfatal stroke, CVD death, hospitalization for heart failure, revascularization HR=0.88 (0.74-1.05) ©2009 New England Journal of Medicine. Used with permission.
  • 45. Glycemic Recommendations forGlycemic Recommendations for Nonpregnant Adults with Diabetes (1)Nonpregnant Adults with Diabetes (1) A1C <7.0%* Preprandial capillary plasma glucose 70–130 mg/dL* (3.9–7.2 mmol/L) Peak postprandial capillary plasma glucose† <180 mg/dL* (<10.0 mmol/L) *Individualize goals based on these values. †Postprandial glucose measurements should be made 1–2 h after the beginning of the meal, generally peak levels in patients with diabetes. ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S21; Table 9.
  • 46. • Goals should be individualized based on –Duration of diabetes –Age/life expectancy –Comorbid conditions –Known CVD or advanced microvascular complications –Hypoglycemia unawareness –Individual patient considerations Glycemic Recommendations forGlycemic Recommendations for Nonpregnant Adults with Diabetes (2)Nonpregnant Adults with Diabetes (2) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S21; Table 9.
  • 47. • More or less stringent glycemic goals may be appropriate for individual patients • Postprandial glucose may be targeted if A1C goals are not met despite reaching preprandial glucose goals Glycemic Recommendations forGlycemic Recommendations for Nonpregnant Adults with Diabetes (3)Nonpregnant Adults with Diabetes (3) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S21; Table 9.
  • 48. Recommendations: Insulin TherapyRecommendations: Insulin Therapy for Type 1 Diabetes (1)for Type 1 Diabetes (1) • Most people with type 1 diabetes – Should be treated with MDI injections (3–4 injections per day of basal and prandial insulin) or continuous subcutaneous insulin infusion (CSII) (A) – Should be educated in how to match prandial insulin dose to carbohydrate intake, premeal blood glucose, and anticipated activity (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S21.
  • 49. Recommendations: Insulin TherapyRecommendations: Insulin Therapy for Type 1 Diabetes (2)for Type 1 Diabetes (2) • Most people with type 1 diabetes should use insulin analogs to reduce hypoglycemia risk (A) • Consider screening those with type 1 diabetes for other autoimmune diseases (thyroid, vitamin B12 deficiency, celiac) as appropriate (B) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S21.
  • 50. • Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacological agent for type 2 diabetes (A) • In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or A1C, consider insulin therapy, with or without additional agents, from the outset (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S22. Recommendations: TherapyRecommendations: Therapy for Type 2 Diabetes (1)for Type 2 Diabetes (1)
  • 51. Recommendations:Recommendations: Therapy for Type 2 Diabetes (2)Therapy for Type 2 Diabetes (2) • If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain the A1C target over 3–6 months, add a second oral agent, a GLP-1 receptor agonist, or insulin (A) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S22.
  • 52. Recommendations:Recommendations: Therapy for Type 2 Diabetes (3)Therapy for Type 2 Diabetes (3) • A patient-centered approach should be used to guide choice of pharmacological agents; considerations include efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia risk, and patient preferences (E) • Due to the progressive nature of type 2 diabetes, insulin therapy is eventually indicated for many patients with type 2 diabetes (B) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S22.
  • 53. Recommendations:Recommendations: Medical Nutrition Therapy (MNT)Medical Nutrition Therapy (MNT) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S22. • Individuals who have prediabetes or diabetes should receive individualized MNT as needed to achieve treatment goals, preferably provided by a registered dietitian familiar with the components of diabetes MNT (A) • Because MNT can result in cost-savings and improved outcomes (B), MNT should be adequately covered by insurance and other payers (E)
  • 54. Look AHEAD (Action for Health inLook AHEAD (Action for Health in Diabetes): Trial Halted EarlyDiabetes): Trial Halted Early 1, 2. Look AHEAD Research Group. Diabetes Care. 2007;30:1374-1383 and Arch Intern Med. 2010;170:1566–1575; http://www.nih.gov/news/health/oct2012/niddk-19.htm. • Intensive lifestyle intervention resulted in1 – Average 8.6% weight loss – Significant reduction of A1C – Reduction in several CVD risk factors • Benefits sustained at 4 years2 • However, trial halted after 11 years of follow-up because there was no significant difference in primary cardiovascular outcome between weight loss, standard care group
  • 55. Recommendations: DiabetesRecommendations: Diabetes Self-Management Education, SupportSelf-Management Education, Support • People with diabetes should receive DSME according to National Standards for Diabetes Self-Management Education and Support at diagnosis and as needed thereafter (B) • Effective self-management, quality of life are key outcomes of DSME; should be measured, monitored as part of care (C) • DSME should address psychosocial issues, since emotional well-being is associated with positive outcomes (C) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S24.
  • 56. Recommendations: DiabetesRecommendations: Diabetes Self-Management Education, SupportSelf-Management Education, Support • DSME and DSMS programs are appropriate venues for people with prediabetes to receive education and support to develop and maintain behaviors that can prevent or delay the onset of diabetes (C) • Because DSME can result in cost-savings and improved outcomes (B), DSME should be reimbursed by third-party payers (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S24.
  • 57. Recommendations: Physical ActivityRecommendations: Physical Activity • Advise people with diabetes to perform at least 150 min/week of moderate-intensity aerobic physical activity (50–70% of maximum heart rate), spread over at least 3 days per week with no more than 2 consecutive days without exercise (A) • In absence of contraindications, adults with type 2 diabetes should be encouraged to perform resistance training at least twice per week (A) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S24.
  • 58. Recommendations:Recommendations: Psychosocial Assessment and CarePsychosocial Assessment and Care • Ongoing part of medical management of diabetes (E) • Psychosocial screening/follow-up: attitudes about diabetes, medical management/outcomes expectations, affect/mood, quality of life, resources, psychiatric history (E) • When self-management is poor, screen for psychosocial problems: depression, diabetes- related anxiety, eating disorders, cognitive impairment (B) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S25-S26.
  • 59. Recommendations: Hypoglycemia (1)Recommendations: Hypoglycemia (1) • Individuals at risk for hypoglycemia should be asked about symptomatic and asymptomatic hypoglycemia at each encounter (C) • Glucose (15–20 g) preferred treatment for conscious individual with hypoglycemia (E) • Glucagon should be prescribed for all individuals at significant risk of severe hypoglycemia and caregivers/family members instructed in administration (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S26.
  • 60. Recommendations: Hypoglycemia (2)Recommendations: Hypoglycemia (2) • Hypoglycemia unawareness or one or more episodes of severe hypoglycemia should trigger re-evaluation of the treatment regimen (E) • Insulin-treated patients with hypoglycemia unawareness or an episode of severe hypoglycemia – Advised to raise glycemic targets to strictly avoid further hypoglycemia for at least several weeks, to partially reverse hypoglycemia unawareness, and to reduce risk of future episodes (A) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S26.
  • 61. Recommendations: Hypoglycemia (3)Recommendations: Hypoglycemia (3) • Ongoing assessment of cognitive function is suggested with increased vigilance for hypoglycemia by the clinician, patient, and caregivers if low cognition and/or declining cognition is found (B) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S26.
  • 62. Recommendations: Bariatric SurgeryRecommendations: Bariatric Surgery • Consider bariatric surgery for adults with BMI ≥35 kg/m2 and type 2 diabetes (B) • After surgery, life-long lifestyle support and medical monitoring is necessary (B) • Insufficient evidence to recommend surgery in patients with BMI <35 kg/m2 outside of a research protocol (E) • Well-designed, randomized controlled trials comparing optimal medical/lifestyle therapy needed to determine long-term benefits, cost-effectiveness, risks (E) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S27.
  • 63. Recommendations: Immunization (1)Recommendations: Immunization (1) • Provide influenza vaccine annually to all diabetic patients ≥6 months of age (C) • Administer pneumococcal polysaccharide vaccine to all diabetic patients ≥2 years (C) – One-time revaccination recommended for those >64 years previously immunized at <65 years if administered >5 years ago – Other indications for repeat vaccination: nephrotic syndrome, chronic renal disease, immunocompromised states ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S28.
  • 64. Recommendations: Immunization (2)Recommendations: Immunization (2) • Administer hepatitis B vaccination to unvaccinated adults with diabetes who are aged 19 through 59 years (C) • Consider administering hepatitis B vaccination to unvaccinated adults with diabetes who are aged ≥60 years (C) ADA. V. Diabetes Care. Diabetes Care 2013;36(suppl 1):S28.
  • 65. VI. PREVENTION AND MANAGEMENT OF DIABETES COMPLICATIONS
  • 66. • CVD is the major cause of morbidity, mortality for those with diabetes • Common conditions coexisting with type 2 diabetes (e.g., hypertension, dyslipidemia) are clear risk factors for CVD • Diabetes itself confers independent risk • Benefits observed when individual cardiovascular risk factors are controlled to prevent/slow CVD in people with diabetes Cardiovascular Disease (CVD) inCardiovascular Disease (CVD) in Individuals with DiabetesIndividuals with Diabetes ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S28-29.
  • 67. Recommendations:Recommendations: Hypertension/Blood Pressure ControlHypertension/Blood Pressure Control Screening and diagnosis • Blood pressure should be measured at every routine visit • Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S28-S29.
  • 68. Recommendations:Recommendations: Hypertension/Blood Pressure ControlHypertension/Blood Pressure Control Goals • People with diabetes and hypertension should be treated to a systolic blood pressure goal of <140 mmHg (B) • Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if it can be achieved without undue treatment burden (C) • Patients with diabetes should be treated to a diastolic blood pressure <80 mmHg (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
  • 69. Recommendations:Recommendations: Hypertension/Blood Pressure ControlHypertension/Blood Pressure Control Treatment (1) • Patients with a blood pressure (BP) >120/80 mmHg should be advised on lifestyle changes to reduce BP (B) • Patients with confirmed BP ≥140/80 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve BP goals (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
  • 70. Recommendations:Recommendations: Hypertension/Blood Pressure ControlHypertension/Blood Pressure Control Treatment (2) • Lifestyle therapy for elevated BP (B) – Weight loss if overweight – DASH-style dietary pattern including reducing sodium, increasing potassium intake – Moderation of alcohol intake – Increased physical activity ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
  • 71. Recommendations:Recommendations: Hypertension/Blood Pressure ControlHypertension/Blood Pressure Control Treatment (3) • Pharmacological therapy for patients with diabetes and hypertension (C) – A regimen that includes either an ACE inhibitor or angiotensin II receptor blocker; if one class is not tolerated, substitute the other • Multiple drug therapy (two or more agents at maximal doses) generally required to achieve BP targets (B) • Administer one or more antihypertensive medications at bedtime (A) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
  • 72. Recommendations:Recommendations: Hypertension/Blood Pressure ControlHypertension/Blood Pressure Control Treatment (4) • If ACE inhibitors, ARBs, or diuretics are used, kidney function, serum potassium levels should be monitored (E) • In pregnant patients with diabetes and chronic hypertension, blood pressure target goals of 110–129/65– 79 mmHg are suggested in interest of long-term maternal health and minimizing impaired fetal growth; ACE inhibitors, ARBs, contraindicated during pregnancy (E) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
  • 73. Recommendations:Recommendations: Dyslipidemia/Lipid Management (1)Dyslipidemia/Lipid Management (1) Screening • In most adult patients, measure fasting lipid profile at least annually (B) • In adults with low-risk lipid values (LDL cholesterol <100 mg/dL, HDL cholesterol >50 mg/dL, and triglycerides <150 mg/dL), lipid assessments may be repeated every 2 years (E) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S31.
  • 74. Recommendations:Recommendations: Dyslipidemia/Lipid Management (2)Dyslipidemia/Lipid Management (2) Treatment recommendations and goals (1) • To improve lipid profile in patients with diabetes, recommend lifestyle modification (A), focusing on – Reduction of saturated fat, trans fat, cholesterol intake – Increased n-3 fatty acids, viscous fiber, plant stanols/sterols – Weight loss (if indicated) – Increased physical activity ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S31.
  • 75. Recommendations:Recommendations: Dyslipidemia/Lipid Management (3)Dyslipidemia/Lipid Management (3) Treatment recommendations and goals (2) • Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels – with overt CVD (A) – without CVD >40 years of age who have one or more other CVD risk factors (A) • For patients at lower risk (e.g., without overt CVD, <40 years of age) (C) – Consider statin therapy in addition to lifestyle therapy if LDL cholesterol remains >100 mg/dL – In those with multiple CVD risk factors ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S31.
  • 76. Recommendations:Recommendations: Dyslipidemia/Lipid Management (4)Dyslipidemia/Lipid Management (4) Treatment recommendations and goals (3) • In individuals without overt CVD – Primary goal is an LDL cholesterol <100 mg/dL (2.6 mmol/L) (B) • In individuals with overt CVD – Lower LDL cholesterol goal of <70 mg/dL (1.8 mmol/L), using a high dose of a statin, is an option (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S31.
  • 77. Recommendations:Recommendations: Dyslipidemia/Lipid Management (5)Dyslipidemia/Lipid Management (5) Treatment recommendations and goals (4) • If targets not reached on maximal tolerated statin therapy – Alternative therapeutic goal: reduce LDL cholesterol ~30–40% from baseline (B) • Triglyceride levels <150 mg/dL (1.7 mmol/L), HDL cholesterol >40 mg/dL (1.0 mmol/L) in men and >50 mg/dL (1.3 mmol/L) in women, are desirable (C) – However, LDL cholesterol–targeted statin therapy remains the preferred strategy (A) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S31.
  • 78. Recommendations:Recommendations: Dyslipidemia/Lipid Management (6)Dyslipidemia/Lipid Management (6) Treatment recommendations and goals (5) • Combination therapy has been shown not to provide additional cardiovascular benefit above statin therapy alone and is not generally recommended (A) • Statin therapy is contraindicated in pregnancy (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S31.
  • 79. Recommendations: Glycemic, BloodRecommendations: Glycemic, Blood Pressure, Lipid Control in AdultsPressure, Lipid Control in Adults A1C <7.0%* Blood pressure <140/80 mmHg† Lipids: LDL cholesterol <100 mg/dL (<2.6 mmol/L)‡ Statin therapy for those with history of MI or age >40+ or other risk factors *More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on: duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations. †Based on patient characteristics and response to therapy, higher or lower systolic blood pressure targets may be appropriate. ‡In individuals with overt CVD, a lower LDL cholesterol goal of <70 mg/dL (1.8 mmol/L), using a high dose of statin, is an option. ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S33; Table 10.
  • 80. Recommendations:Recommendations: Antiplatelet Agents (1)Antiplatelet Agents (1) • Consider aspirin therapy (75–162 mg/day) (C) – As a primary prevention strategy in those with type 1 or type 2 diabetes at increased cardiovascular risk (10-year risk >10%) – Includes most men >50 years of age or women >60 years of age who have at least one additional major risk factor • Family history of CVD • Hypertension • Smoking • Dyslipidemia • Albuminuria ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S32-S33.
  • 81. Recommendations:Recommendations: Antiplatelet Agents (2)Antiplatelet Agents (2) • Aspirin should not be recommended for CVD prevention for adults with diabetes at low CVD risk, since potential adverse effects from bleeding likely offset potential benefits (C) • 10-year CVD risk <5%: men <50 and women <60 years of age with no major additional CVD risk factors • In patients in these age groups with multiple other risk factors (10-year risk 5–10%), clinical judgment is required (E) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S33.
  • 82. Recommendations:Recommendations: Antiplatelet Agents (3)Antiplatelet Agents (3) • Use aspirin therapy (75–162 mg/day) – Secondary prevention strategy in those with diabetes with a history of CVD (A) • For patients with CVD and documented aspirin allergy – Clopidogrel (75 mg/day) should be used (B) • Combination therapy with aspirin (75–162 mg/day) and clopidogrel (75 mg/day) – Reasonable for up to a year after an acute coronary syndrome (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S33-S34.
  • 83. Recommendations:Recommendations: Smoking CessationSmoking Cessation • Advise all patients not to smoke or use tobacco products (A) • Include smoking cessation counseling and other forms of treatment as a routine component of diabetes care (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34.
  • 84. Recommendations:Recommendations: Coronary Heart Disease ScreeningCoronary Heart Disease Screening • In asymptomatic patients, routine screening for CAD is not recommended, as it does not improve outcomes as long as CVD risk factors are treated (A) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34.
  • 85. Recommendations:Recommendations: Coronary Heart Disease Treatment (1)Coronary Heart Disease Treatment (1) • To reduce risk of cardiovascular events in patients with known CVD, consider – ACE inhibitor (C) – Aspirin* (A) – Statin therapy* (A) • In patients with a prior MI – β-blockers should be continued for at least 2 years after the event (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34. *If not contraindicated.
  • 86. Recommendations:Recommendations: Coronary Heart Disease Treatment (2)Coronary Heart Disease Treatment (2) • Avoid thiazolidinedione treatment in patients with symptomatic heart failure (C) • Metformin use in patients with stable CHF – Indicated if renal function is normal (C) – Should be avoided in unstable or hospitalized patients with CHF (C) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34.
  • 87. Recommendations: NephropathyRecommendations: Nephropathy • To reduce the risk or slow the progression of nephropathy – Optimize glucose control (A) – Optimize blood pressure control (A) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34-S35.
  • 88. Recommendations:Recommendations: Nephropathy ScreeningNephropathy Screening • Assess urine albumin excretion annually (B) – In type 1 diabetic patients with diabetes duration of ≥5 years – In all type 2 diabetic patients at diagnosis • Measure serum creatinine at least annually (E) – In all adults with diabetes regardless of degree of urine albumin excretion – Serum creatinine should be used to estimate GFR and stage level of chronic kidney disease, if present ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34.
  • 89. Recommendations:Recommendations: Nephropathy Treatment (1)Nephropathy Treatment (1) • Nonpregnant patient with modestly elevated (30-299 mg/day) (C) or higher levels (≥300 mg/day) (A) of urinary albumin excretion – Use either ACE inhibitors or ARBs • Reduction of protein intake may improve measures of renal function (urine albumin excretion rate, GFR) (B) – To 0.8–1.0 g/kg body wt per day in those with diabetes, earlier stages of CKD – To 0.8 g/kg body wt per day in later stages of CKD ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S34-S35.
  • 90. Recommendations:Recommendations: Nephropathy Treatment (2)Nephropathy Treatment (2) • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium (E) • Reasonable to continue monitoring urine albumin excretion to assess both response to therapy and disease progression (E) • When estimated GFR is <60 mL/min/ 1.73 m2 , evaluate and manage potential complications of CKD (E) ADA. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S35.
  • 91. Recommendations:Recommendations: Nephropathy Treatment (3)Nephropathy Treatment (3) • Consider referral to a physician experienced in care of kidney disease (B) – Uncertainty about etiology of kidney disease – Difficult management issues – Advanced kidney disease ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S35.
  • 92. Definitions of Abnormalities inDefinitions of Abnormalities in Albumin ExcretionAlbumin Excretion Category Spot collection (µg/mg creatinine) Normal <30 Increased urinary albumin excretion* ≥30 ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S35; Table 11. *Historically, ratios between 30 and 299 have been called microalbuminuria and those 300 or greater have been called macroalbuminuria (or clinical albuminuria).
  • 93. Stages of Chronic Kidney DiseaseStages of Chronic Kidney Disease Stage Description GFR (mL/min per 1.73 m2 body surface area) 1 Kidney damage* with normal or increased GFR ≥90 2 Kidney damage* with mildly decreased GFR 60–89 3 Moderately decreased GFR 30–59 4 Severely decreased GFR 15–29 5 Kidney failure <15 or dialysis *Kidney damage defined as abnormalities on pathologic, urine, blood, or imaging tests. GFR = glomerular filtration rate ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S35-S36; Table 12.
  • 94. Management of CKD in Diabetes (1)Management of CKD in Diabetes (1) GFR Recommended All patients Yearly measurement of creatinine, urinary albumin excretion, potassium 45-60 Referral to nephrology if possibility for nondiabetic kidney disease exists Consider dose adjustment of medications Monitor eGFR every 6 months Monitor electrolytes, bicarbonate, hemoglobin, calcium, phosphorus, parathyroid hormone at least yearly Assure vitamin D sufficiency Consider bone density testing Referral for dietary counselling ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S37; Table 13; Adapted from http://www.kidney.org/professionals/KDOQI/guideline_diabetes/.
  • 95. Management of CKD in Diabetes (2)Management of CKD in Diabetes (2) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S37; Table 13; Adapted from http://www.kidney.org/professionals/KDOQI/guideline_diabetes/. GFR Recommended 30-44 Monitor eGFR every 3 months Monitor electrolytes, bicarbonate, calcium, phosphorus, parathyroid hormone, hemoglobin, albumin weight every 3–6 months Consider need for dose adjustment of medications <30 Referral to nephrologist
  • 96. Recommendations: RetinopathyRecommendations: Retinopathy • To reduce the risk or slow the progression of retinopathy – Optimize glycemic control (A) – Optimize blood pressure control (A) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S36.
  • 97. Recommendations:Recommendations: Retinopathy Screening (1)Retinopathy Screening (1) • Initial dilated and comprehensive eye examination by an ophthalmologist or optometrist – Adults and children aged 10 years or older with type 1 diabetes • Within 5 years after diabetes onset (B) – Patients with type 2 diabetes • Shortly after diagnosis of diabetes (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S35.
  • 98. Recommendations:Recommendations: Retinopathy Screening (2)Retinopathy Screening (2) • Subsequent examinations for type 1 and type 2 diabetic patients (B) – Should be repeated annually by an ophthalmologist or optometrist • Less frequent exams (every 2–3 years) (B) – May be considered following one or more normal eye exams • More frequent examinations required if retinopathy is progressing (B) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S35-S36.
  • 99. Recommendations:Recommendations: Retinopathy Screening (3)Retinopathy Screening (3) • High-quality fundus photographs – Can detect most clinically significant diabetic retinopathy (E) • Interpretation of the images – Performed by a trained eye care provider (E) • While retinal photography may serve as a screening tool for retinopathy, it is not a substitute for a comprehensive eye exam – Perform comprehensive eye exam at least initially and at intervals thereafter as recommended by an eye care professional (E) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S36.
  • 100. Recommendations:Recommendations: Retinopathy Screening (4)Retinopathy Screening (4) • Women with preexisting diabetes who are planning pregnancy or who have become pregnant (B) – Comprehensive eye examination – Counseled on risk of development and/or progression of diabetic retinopathy • Eye examination should occur in the first trimester (B) – Close follow-up throughout pregnancy – For 1 year postpartum ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S36.
  • 101. Recommendations:Recommendations: Retinopathy Treatment (1)Retinopathy Treatment (1) • Promptly refer patients with any level of macular edema, severe NPDR, or any PDR – To an ophthalmologist knowledgeable and experienced in management, treatment of diabetic retinopathy (A) • Laser photocoagulation therapy is indicated (A) – To reduce risk of vision loss in patients with • High-risk PDR • Clinically significant macular edema • Some cases of severe NPDR ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S36.
  • 102. Recommendations:Recommendations: Retinopathy Treatment (2)Retinopathy Treatment (2) • Anti-vascular endothelial growth factor (VEGF) therapy is indicated for diabetic macular edema (A) • Presence of retinopathy – Not a contraindication to aspirin therapy for cardioprotection, as this therapy does not increase the risk of retinal hemorrhage (A) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S36.
  • 103. Recommendations:Recommendations: Neuropathy Screening, Treatment (1)Neuropathy Screening, Treatment (1) • All patients should be screened for distal symmetric polyneuropathy (DPN) (B) – At diagnosis of type 2 diabetes and 5 years after diagnosis of type 1 diabetes – At least annually thereafter using simple clinical tests • Electrophysiological testing rarely needed – Except in situations where clinical features are atypical (E) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S37.
  • 104. Recommendations:Recommendations: Neuropathy Screening, Treatment (2)Neuropathy Screening, Treatment (2) • Screening for signs and symptoms of cardiovascular autonomic neuropathy – Should be instituted at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes – Special testing rarely needed; may not affect management or outcomes (E) • Medications for relief of specific symptoms related to DPN, autonomic neuropathy are recommended – Improve quality of life of the patient (E) ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S37.
  • 105. Recommendations: Foot Care (1)Recommendations: Foot Care (1) • For all patients with diabetes, perform an annual comprehensive foot examination to identify risk factors predictive of ulcers and amputations (B) – Inspection – Assessment of foot pulses – Test for loss of protective sensation: 10-g monofilament plus testing any one of • Vibration using 128-Hz tuning fork • Pinprick sensation • Ankle reflexes • Vibration perception threshold ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S38.
  • 106. Upper panel •To perform the 10-g monofilament test, place the device perpendicular to the skin, with pressure applied until the monofilament buckles •Hold in place for 1 second and then release Lower panel •The monofilament test should be performed at the highlighted sites while the patient’s eyes are closed Boulton AJM, et al. Diabetes Care. 2008;31:1679-1685. Recommendations: Foot Care (2)Recommendations: Foot Care (2)
  • 107. • Provide general foot self-care education (B) • Use multidisciplinary approach – Individuals with foot ulcers, high-risk feet; especially prior ulcer or amputation (B) • Refer patients to foot care specialists for ongoing preventive care, life-long surveillance (C) – Smokers – Loss of protective sensation or structural abnormalities – History of prior lower-extremity complications ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S38. Recommendations: Foot Care (3)Recommendations: Foot Care (3)
  • 108. • Initial screening for peripheral arterial disease (PAD) (C) – Include a history for claudication, assessment of pedal pulses – Consider obtaining an ankle-brachial index (ABI); many patients with PAD are asymptomatic • Refer patients with significant claudication or a positive ABI for further vascular assessment (C) – Consider exercise, medications, surgical options ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S38. Recommendations: Foot Care (4)Recommendations: Foot Care (4)
  • 109. VII. ASSESSMENT OF COMMON COMORBID CONDITIONS
  • 110. Recommendations: Assessment ofRecommendations: Assessment of Common Comorbid ConditionsCommon Comorbid Conditions • For patients with risk factors, signs or symptoms, consider assessment and treatment for common diabetes-associated conditions (B) • Common comorbidities for which increased risk is associated with diabetes ADA. VII. Assessment of Common Comorbid Conditions. Diabetes Care. 2013;36(suppl 1):S39; Table 14. Hearing impairment Certain cancers Obstructive sleep apnea Fractures Fatty liver disease Cognitive impairment Low testosterone in men Depression Periodontal disease
  • 111. VIII. DIABETES CARE IN SPECIFIC POPULATIONS
  • 112. Recommendations: PediatricRecommendations: Pediatric Glycemic Control (Type 1 Diabetes)Glycemic Control (Type 1 Diabetes) • As is the case for all children, children with diabetes or prediabetes should be encouraged to engage in at least 60 minutes of physical activity each day (B) • Consider age when setting glycemic goals in children and adolescents with type 1 diabetes (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S40-S41.
  • 113. Recommendations: PediatricRecommendations: Pediatric Nephropathy (Type 1 Diabetes)Nephropathy (Type 1 Diabetes) • Annual screening for microalbuminuria, with a random spot urine sample for albumin-to-creatinine (ACR) ratio (B) – Consider once child is 10 years of age and has had diabetes for 5 years • Confirmed, elevated ACR on two additional urine specimens from different days – Treat with an ACE inhibitor, titrated to normalization of albumin excretion (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41.
  • 114. Recommendations: PediatricRecommendations: Pediatric Hypertension (Type 1 Diabetes) (1)Hypertension (Type 1 Diabetes) (1) • Measure blood pressure (BP) at each routine visit; confirm high-normal BP or hypertension on a separate day (B) • Treat high-normal BP (systolic or diastolic consistently above 90th percentile for age, sex, and height) with – Dietary intervention; exercise aimed at weight control and increased physical activity • If target BP is not reached with 3–6 months of lifestyle intervention, consider pharmacologic treatment (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41.
  • 115. • Pharmacologic treatment of hypertension – Systolic or diastolic blood pressure consistently above the 95th percentile for age, sex, and height Or – Consistently >130/80 mmHg, if 95% exceeds that value • Initiate treatment as soon as diagnosis is confirmed (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41. Recommendations: PediatricRecommendations: Pediatric Hypertension (Type 1 Diabetes) (2)Hypertension (Type 1 Diabetes) (2)
  • 116. • ACE inhibitors – Consider for initial treatment of hypertension, following appropriate reproductive counseling due to potential teratogenic effects (E) • Goal of treatment – Blood pressure consistently <130/80 mmHg or below the 90th percentile for age, sex, and height, whichever is lower (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41. Recommendations: PediatricRecommendations: Pediatric Hypertension (Type 1 Diabetes) (3)Hypertension (Type 1 Diabetes) (3)
  • 117. Recommendations: PediatricRecommendations: Pediatric Dyslipidemia (Type 1 Diabetes) (1)Dyslipidemia (Type 1 Diabetes) (1) Screening (1) • If family history of hypercholesterolemia or a cardiovascular event before age 55 years, or if family history is unknown – Perform fasting lipid profile on children >2 years of age soon after diagnosis (after glucose control has been established) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41.
  • 118. Screening (2) • If family history is not of concern – Consider first lipid screening at puberty (≥10 years) (E) • All children diagnosed with diabetes at or after puberty – Perform fasting lipid profile soon after diagnosis (after glucose control has been established) (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41. Recommendations: PediatricRecommendations: Pediatric Dyslipidemia (Type 1 Diabetes) (2)Dyslipidemia (Type 1 Diabetes) (2)
  • 119. Screening (3) • For both age-groups, if lipids are abnormal – Annual monitoring is reasonable • If LDL cholesterol values are within accepted risk levels (<100 mg/dL [2.6 mmol/L]) – Repeat lipid profile every 5 years (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41. Recommendations: PediatricRecommendations: Pediatric Dyslipidemia (Type 1 Diabetes) (3)Dyslipidemia (Type 1 Diabetes) (3)
  • 120. Treatment • Initial therapy: optimize glucose control, MNT using Step 2 AHA diet aimed at decreasing dietary saturated fat (E) • > age 10 years, statin reasonable in those (after MNT and lifestyle changes) with – LDL cholesterol >160 mg/dL (4.1 mmol/L) or – LDL cholesterol >130 mg/dL (3.4 mmol/L) and one or more CVD risk factors (E) • Goal: LDL cholesterol <100 mg/dL (2.6 mmol/L) (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S41. MNT=medical nutrition therapy Recommendations: PediatricRecommendations: Pediatric Dyslipidemia (Type 1 Diabetes) (4)Dyslipidemia (Type 1 Diabetes) (4)
  • 121. • First ophthalmologic examination – Obtain once child is ≥10 years of age; has had diabetes for 3–5 years (B) • After initial examination – Annual routine follow-up generally recommended – Less frequent examinations may be acceptable on advice of an eye care professional (E) Recommendations: PediatricRecommendations: Pediatric Retinopathy (Type 1 Diabetes)Retinopathy (Type 1 Diabetes) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S42.
  • 122. Recommendations: PediatricRecommendations: Pediatric Celiac Disease (Type 1 Diabetes) (1)Celiac Disease (Type 1 Diabetes) (1) • Children with type 1 diabetes – Screen for celiac disease by measuring tissue transglutaminase or antiendomysial antibodies, with documentation of normal total serum IgA levels, soon after the diagnosis of diabetes (E) • Repeat testing in children with – Growth failure – Failure to gain weight, weight loss – Diarrhea, flatulence, abdominal pain, or signs of malabsorption – Frequent unexplained hypoglycemia or deterioration in glycemic control (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S42.
  • 123. • Asymptomatic children with positive antibodies – Refer to a gastroenterologist for evaluation with possible endoscopy and biopsy (E) • Children with biopsy-confirmed celiac disease – Place on a gluten-free diet – Consult with a dietitian experienced in managing both diabetes and celiac disease (B) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S42. Recommendations: PediatricRecommendations: Pediatric Celiac Disease (Type 1 Diabetes) (2)Celiac Disease (Type 1 Diabetes) (2)
  • 124. Recommendations: PediatricRecommendations: Pediatric Hypothyroidism (Type 1 Diabetes)Hypothyroidism (Type 1 Diabetes) • Children with type 1 diabetes – Screen for thyroid peroxidase, thyroglobulin antibodies soon after diagnosis (E) • Thyroid-stimulating hormone (TSH) concentrations – Measure after metabolic control established • If normal, recheck every 1–2 years; or • If patient develops symptoms of thyroid dysfunction, thyromegaly, or an abnormal growth rate (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S43.
  • 125. Recommendations: Transition fromRecommendations: Transition from Pediatric to Adult CarePediatric to Adult Care • As teens transition into emerging adulthood, health care providers and families must recognize their many vulnerabilities (B) and prepare the developing teen, beginning in early to mid adolescence and at least 1 year prior to the transition (E) • Both pediatricians and adult health care providers should assist in providing support and links to resources for the teen and emerging adult (B) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S43.
  • 126. Recommendations:Recommendations: Preconception Care (1)Preconception Care (1) • A1C levels should be as close to normal as possible (7%) in an individual patient before conception is attempted (B) • Starting at puberty, incorporate preconception counseling in routine diabetes clinic visit for all women of childbearing potential (C) • Women with diabetes contemplating pregnancy should be evaluated and, if indicated, treated for diabetic retinopathy, nephropathy, neuropathy, CVD (B) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S44.
  • 127. • Medications should be evaluated prior to conception, since drugs commonly used to treat diabetes and its complications may be contraindicated or not recommended in pregnancy, including statins, ACE inhibitors, ARBs, and most noninsulin therapies (E) • Since many pregnancies are unplanned, consider potential risks/benefits of medications contraindicated in pregnancy in all women of childbearing potential; counsel accordingly (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S44. Recommendations:Recommendations: Preconception Care (2)Preconception Care (2)
  • 128. Recommendations: Older Adults (1)Recommendations: Older Adults (1) • Functional, cognitively intact older adults with significant life expectancies should receive diabetes care using goals developed for younger adults (E) • Glycemic goals for those not meeting the above criteria may be relaxed using individual criteria, but hyperglycemia leading to symptoms or risk of acute hyperglycemic complications should be avoided in all patients (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S44.
  • 129. Recommendations: Older Adults (2)Recommendations: Older Adults (2) • Treat other cardiovascular risk factors with consideration of the time frame of benefit and the individual patient (E) • Treatment of hypertension is indicated in virtually all older adults; lipid, aspirin therapy may benefit those with life expectancy equal to time frame of primary/secondary prevention trials (E) • Individualize screening for diabetes complications with attention to those leading to functional impairment (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S44.
  • 130. Recommendations: Cystic Fibrosis-Recommendations: Cystic Fibrosis- Related Diabetes (CFRD) (1)Related Diabetes (CFRD) (1) • Annual screening for CFRD with OGTT should begin by age 10 years in all patients with cystic fibrosis who do not have CFRD (B) – Use of A1C as a screening test for CFRD is not recommended (B) • During a period of stable health, diagnosis of CFRD can be made in patients with cystic fibrosis according to usual glucose criteria (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S45.
  • 131. Recommendations: Cystic Fibrosis-Recommendations: Cystic Fibrosis- Related Diabetes (CFRD) (2)Related Diabetes (CFRD) (2) • Patients with CFRD should be treated with insulin to attain individualized glycemic goals (A) • Annual monitoring for complications of diabetes is recommended, beginning 5 years after the diagnosis of CFRD (E) ADA. VIII. Diabetes Care in Specific Populations. Diabetes Care. 2013;36(suppl 1):S45.
  • 132. IX. DIABETES CARE IN SPECIFIC SETTINGS
  • 133. Recommendations:Recommendations: Diabetes Care in the Hospital (1)Diabetes Care in the Hospital (1) • All patients with diabetes admitted to the hospital should have their diabetes clearly identified in the medical record (E) • All patients with diabetes should have an order for blood glucose monitoring, with results available to all members of the health care team (E) ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S45.
  • 134. Recommendations:Recommendations: Diabetes Care in the Hospital (2)Diabetes Care in the Hospital (2) • Goals for blood glucose levels – Critically ill patients: Initiate insulin therapy for treatment of persistent hyperglycemia starting at a threshold of no greater than 140-180 mg/dL (7.8–10 mmol/L) (A) – More stringent goals, such as 110-140 mg/dL (6.1–7.8 mmol/L) may be appropriate for selected patients, if achievable without significant hypoglycemia (C) – Critically ill patients require an IV insulin protocol with demonstrated efficacy, safety in achieving desired glucose range without increasing risk for severe hypoglycemia (E) ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S45.
  • 135. Recommendations:Recommendations: Diabetes Care in the Hospital (3)Diabetes Care in the Hospital (3) • Goals for blood glucose levels – Noncritically ill patients: No clear evidence for specific blood glucose goals – If treated with insulin, premeal blood glucose targets (if safely achieved) • Generally <140 mg/dL (7.8 mmol/L) with random blood glucose <180 mg/dL (10.0 mmol/L) – More stringent targets may be appropriate in stable patients with previous tight glycemic control – Less stringent targets may be appropriate in those with severe comorbidities (E) ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S46.
  • 136. Recommendations:Recommendations: Diabetes Care in the Hospital (4)Diabetes Care in the Hospital (4) • Scheduled subcutaneous insulin with basal, nutritional, and correction components is the preferred method for achieving and maintaining glucose control in non-critically ill patients (C) ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S46.
  • 137. Recommendations:Recommendations: Diabetes Care in the Hospital (5)Diabetes Care in the Hospital (5) • Initiate glucose monitoring in any patient not known to be diabetic who receives therapy associated with high-risk for hyperglycemia – High-dose glucocorticoid therapy, initiation of enteral or parenteral nutrition, or other medications such as octreotide or immunosuppressive medications (B) • If hyperglycemia is documented and persistent, consider treating such patients to the same glycemic goals as patients with known diabetes (E) ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S46.
  • 138. Recommendations:Recommendations: Diabetes Care in the Hospital (6)Diabetes Care in the Hospital (6) • A hypoglycemia management protocol should be adopted and implemented by each hospital or hospital system (E) • Obtain A1C for all patients (E) – If results within previous 2–3 months unavailable – With diabetes risk factors who exhibit hyperglycemia • Patients with hyperglycemia without a diagnosis of diabetes: document plans for follow-up testing and care at discharge (E) ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S46.
  • 139. Diabetes Care in the Hospital:Diabetes Care in the Hospital: NICE-SUGAR Study (1)NICE-SUGAR Study (1) • Largest randomized controlled trial to date • Tested effect of tight glycemic control (target 81–108 mg/dL) on outcomes among 6,104 critically ill participants • Majority (>95%) required mechanical ventilation ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S46.
  • 140. Diabetes Care in the Hospital:Diabetes Care in the Hospital: NICE-SUGAR Study (2)NICE-SUGAR Study (2) • In both surgical/medical patients, 90-day mortality significantly higher in intensively treated vs conventional group (target 144–180 mg/dL) – Severe hypoglycemia more common (6.8% vs 0.5%; P<0.001) – Findings strongly suggest may not be necessary to target blood glucose levels <140 mg/dL; highly stringent target of <110 mg/dL may be dangerous ADA. IX. Diabetes Care in Specific Settings. Diabetes Care. 2013;36(suppl 1):S46.
  • 141. X. STRATEGIES FOR IMPROVING DIABETES CARE
  • 142. Recommendations: Strategies forRecommendations: Strategies for Improving Diabetes Care (1)Improving Diabetes Care (1) ADA. X. Strategies for Improving Diabetes Care. Diabetes Care. 2013;36(suppl 1):S49-S50. • Care should be aligned with components of the Chronic Care Model to ensure productive interactions between a prepared proactive practice team and an informed activated patient (A) • When feasible, care systems should support team-based care, community involvement, patient registries, and embedded decision support tools to meet patient needs (B)
  • 143. Recommendations: Strategies forRecommendations: Strategies for Improving Diabetes Care (2)Improving Diabetes Care (2) ADA. X. Strategies for Improving Diabetes Care. Diabetes Care. 2013;36(suppl 1):S50. • Treatment decisions should be timely and based on evidence-based guidelines that are tailored to individual patient preferences, prognoses, and comorbidities (B) • A patient-centered communication style should be employed that incorporates patient preferences, assesses literacy and numeracy, and addresses cultural barriers to care (B)
  • 144. Objective 1:Objective 1: Optimize Provider and Team BehaviorOptimize Provider and Team Behavior ADA. X. Strategies for Improving Diabetes Care. Diabetes Care. 2013;36(suppl 1):S50. • Care team should prioritize timely, appropriate intensification of lifestyle and/or pharmaceutical therapy – Patients who have not achieved beneficial levels of blood pressure, lipid, or glucose control • Strategies include – Explicit goal setting with patients – Identifying and addressing barriers to care – Integrating evidence-based guidelines – Incorporating care management teams
  • 145. Objective 2:Objective 2: Support Patient Behavior ChangeSupport Patient Behavior Change • Implement a systematic approach to support patient behavior change efforts – a) Healthy lifestyle: physical activity, healthy eating, nonuse of tobacco, weight management, effective coping – b) Disease self-management: medication taking and management, self-monitoring of glucose and blood pressure when clinically appropriate – c) Prevention of diabetes complications: self-monitoring of foot health, active participation in screening for eye, foot, and renal complications, and immunizations ADA. X. Strategies for Improving Diabetes Care. Diabetes Care. 2013;36(suppl 1):S50.
  • 146. Objective 3:Objective 3: Change the System of CareChange the System of Care • The most successful practices have an institutional priority for providing high quality of care – Basing care on evidence-based guidelines – Expanding the role of teams and staff – Redesigning the processes of care – Implementing electronic health record tools – Activating and educating patients – Identifying and/or developing community resources and public policy that supports healthy lifestyles – Alterations in reimbursement ADA. X. Strategies for Improving Diabetes Care. Diabetes Care. 2013;36(suppl 1):S50.